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 Abstract 
 
 Intellectual disability (ID) refers to reduced cognitive function, apparent before 
the age of 18, that negatively affects a person's learning and adaptive capacity. 
Approximately 1-3% of the population is affected with ID, males more than females, and 
most in the mild-to-moderate range.  ID creates financial, logistical and psychosocial 
challenges for affected persons and their families and caregivers.  It is estimated that up 
to 50% of ID has a genetic cause.  Molecular genetic diagnosis may help in obtaining 
services and has important implications for family members, but can be elusive.  Genes 
causing ID are known to be over-represented on the X chromosome.  Over 160 X-linked 
intellectual disability (XLID) syndromes and > 100 XLID genes have been identified to 
date.  Greenwood Genetic Center (GGC) offers a next-generation sequencing panel of 
approximately 90 XLID genes.  The diagnostic potential offered by large gene panels is 
offset by the challenges of interpreting variants of uncertain significance (VUS).  In this 
study, molecular and clinical data from 592 cases submitted for XLID panel testing were 
evaluated for patterns of phenotype and genotype, in order to further the understanding of 
XLID.  We found a low pathogenic hit rate, a high VUS-only rate and a general absence 
of statistically significant phenotypic patterns.  These results highlight the need for 
appropriate patient selection, full and accurate phenotype reporting and open sharing of 
information in order to interpret and learn from the results of genetic testing. 
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Chapter 1. Introduction 
 
1.1 Intellectual Disability Overview 
 Intellectual Disability (ID) is defined as reduced intellectual capacity that is 
apparent before the age of 18 years, and which creates significant limitations on the 
individual's ability to learn, understand, communicate and adapt (American Association 
on Intellectual and Developmental Disabilities (AAIDD), 2014).  Intellectual capacity is 
commonly reported in terms of an Intelligence Quotient, or IQ score.  Average IQ is 
defined as a score of 100.  ID is diagnosed when an individual's IQ falls > 2 standard 
deviations below the age-appropriate mean (Tirosh & Jaffe, 2011).  ID is considered to 
begin at IQ of 70-75 and below, and can be characterized as mild, moderate, severe or 
profound, with measurable decreases in the individual's functional capacity with 
increasing ID severity.  Approximately 1-3% of the population is affected with ID, most 
in the mild-to-moderate range.  Prevalence of ID is 30-40% higher in males, perhaps 
reflecting the influence of X-linked genes on brain development and function (Leonard & 
Wen, 2002; Nguyen & Disteche, 2006).  Individuals with ID may have difficulty living 
independently, securing or maintaining employment or caring for themselves.  This 
creates financial and logistical challenges for the affected individuals and for their 
families, caregivers, and communities. 
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 ID may exist as part of a recognizable, consistent constellation of intellectual, 
physical and/or functional anomalies that are due to a single underlying etiology, in 
which case it is considered syndromic ID.  Common examples include Down syndrome, 
Fragile X syndrome and untreated Phenylketonuria (PKU).  On the other hand, in non-
syndromic forms, ID may be the only finding, brought to attention by the child's failure to 
develop along a typical time course, or the loss of developmental milestones.  There may 
be other anomalies that do not fall within a recognizable pattern.  While some reports 
state that only 20% of all ID has an identifiable cause (Rauch et al., 2006), others 
estimate that genetic factors may contribute in up to 85% of all cases (Curry et al., 1997). 
1.2 Living With and Caring For Intellectual Disability 
 By definition, individuals with ID face difficulties in conducting the tasks of daily 
living.  They require assistance ranging from minor supervision and aid to round-the-
clock, total care.  In addition to their intellectual challenges, individuals with ID may 
have significant medical and behavioral problems that must be managed.  Studies have 
demonstrated that the responsibility for care falls mainly on families, most particularly 
mothers, a majority of whom may not have additional, outside employment (Rowbotham, 
Cuskelly, & Carroll, 2011).  Caregivers must personally provide care, arrange and attend 
medical and service appointments, negotiate with parties such as educators and third 
party payors, and pay for expenses related to care and services for their family member 
with ID.  This, compounded with the additional expense of care for a disabled child or 
adult, places enormous strain on caregivers.  The ability to provide care is directly related 
to socioeconomic status and age, with older and younger parents having fewer resources 
than those in the 45-to-54 age group (Parish, Rose, & Swaine, 2010).  Moreover, 
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intellectual disability is more common in individuals of lower socioeconomic status, 
meaning that the population with the fewest resources for providing care and obtaining 
services for disabled individuals has the greatest need of those services (Emerson, 2012).  
Children with ID grow up to be adults with ID, who continue to require lifelong 
supervision and care.  The burden and expense to their families/caregivers is therefore 
lifelong as well.  As parents age, there can be considerable distress surrounding issues of 
care beyond the time the parents are able to provide it themselves (Dillenburger & 
McKerr, 2011).  As many as 62% of caregivers have no alternative care plan in place for 
if or when they are no longer able to provide care personally (Anderson, Larson & 
Wuorio, 2011).  This has become an issue of increasing significance as care and life 
expectancy for individuals with intellectual disability have improved markedly over the 
last several decades.  For instance, life expectancy for individuals with Down syndrome 
in the 1980s was approximately 25 years, but in the late 1990s had increased to 49 and is 
currently estimated at the mid-50s (Coppus, 2013; Yang, Rasmussen, & Friedman, 2002).  
As with any aging persons, individuals with ID face increasing health concerns as they 
grow older, a factor that increases the complexity and cost of their care (Strydom et al., 
2010), even as their parents experience the challenges of aging themselves (Bittles et al., 
2002). 
 A major source of services for the intellectually disabled is state-funded 
assistance programs, the history of which is nicely reviewed by Harold Pollack (Pollack, 
2011).  The largest of these is Medicaid, which funds not only medical services, but other 
educational and disability resource services.  The recent decline in the United States 
economy and associated tax revenue has necessitated cost-cutting measures among state 
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governmental agencies, including those programs providing services for the disabled.  
The early 2000s saw a dramatic drop in the average yearly increase in state funding for 
disability services, from 6.6% to less than 2%.  Between 2008 and 2009, 47 states 
experienced percentage decreases and there was a drop in actual dollar expenditures for 
disability services in 23 states (Braddock et al., 2011).  Perhaps most unfortunately, the 
states with the lowest pre-recession disability funding levels (that is, states in which the 
disabled were already at a disadvantage) were also the states that implemented the 
deepest cuts in disability services funding (Pollack, 2011). 
 In addition to the financial and logistical burdens borne by individuals with ID 
and their families, there are social burdens as well.  Intellectual impairment remains one 
of the disabilities that is least understood and accepted in many modern cultures (Scior, 
2011).  The lack of awareness can lead to negative attitudes about people with ID, 
manifested in such ways as bullying, violent/hate crimes, discrimination, avoidance, lack 
of inclusion and stigmatization (Ali, Hassiotis, Strydom, & King, 2012; Scior, 2011; 
Werner, Corrigan, Ditchman, & Sokol, 2012).  Stigmatization may be directed not just 
toward individuals with ID, but toward their families, friends and associates as well, 
known as "courtesy" or "affiliate" stigma (Ali et al., 2012).  Tragically, affected 
individuals exposed to such negative attitudes often internalize them and adopt self-
deprecating thoughts and attitudes ("self-stigma"), a phenomenon that has been 
documented in individuals with ID for many decades (Ali et al., 2012).  
1.3 X-Linked Intellectual Disability (XLID) 
  By definition, X-linked ID follows an X-linked pattern of inheritance, whether or 
not a specific X-linked genetic cause has been identified.  Alternatively, it is ID that is 
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caused by mutation of an X-linked gene, with or without a family history.  Depending on 
the underlying etiology, an X-linked family history may present with affected males only; 
with both males and females affected, equally or differentially; or with only females 
affected, due to male lethality.  XLID may be syndromic (ID plus additional features), 
non-syndromic (ID only), or neuromuscular (for instance, associated with 
Duchenne/Becker muscular dystrophy).  Approximately 160 XLID syndromes have been 
described; however, the majority of XLID is non-syndromic (Stevenson, Schwartz & 
Rogers 2012; Lubs, Stevenson & Schwartz, 2012).  It is estimated that ~10% of genes on 
the X chromosome, or at least 120 genes, may contribute to XLID; over 100 of these 
have been identified to date (Lubs, Stevenson & Schwartz et al., 2012).  
1.4 Selected Features Often Associated with Intellectual Disability 
   1.4.1 Abnormal head size. 
 The biological function of the cranium (brain vault of the skull) is to enclose and 
protect the brain within it.  Like a motorcycle helmet, this function is best served when 
the fit is neither too loose nor too tight.  The dimensions of the cranium are therefore 
determined by the volume of the brain.  Measurement of the occipito-frontal 
circumference (OFC) is a useful clinical tool for estimating whether an individual's brain 
volume falls within the expected range for their age and sex.  Head size in ID may be 
smaller (microcephaly) or larger (macrocephaly) than expected.  In general, a relative 
head size that changes over time (that is, an increasing or decreasing OFC percentile) is 
more worrisome than an OFC that remains stable in terms of percentile.  It should be 
noted that a recent meta-analysis of worldwide human growth data has demonstrated that 
OFC means can vary significantly according to geographical, national or ethnic 
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backgrounds (Natale & Rajagopalan, 2014).  The authors concluded that universal use of 
the World Health Organization (WHO) OFC standards may lead to inappropriate 
characterization of young children as having micro- or macrocephaly. 
 Microcephaly, its causes, evaluation and implications have been thoroughly 
discussed in a recent review (Woods & Parker, 2013).  Primary microcephaly is often 
defined as an OFC at least two standard deviations smaller than the mean at birth (and 
often detected prenatally).  Some would argue that three standard deviations is a more 
appropriate cutoff, and that head shape should be taken into consideration as well (Woods 
& Parker, 2013).  In primary microcephaly, the fetal brain does not grow to typical size, 
therefore the cranium also remains small.  Brain architecture may be essentially normal 
or may show underdevelopment and/or abnormal formation of specific structures.  The 
causes of primary microcephaly are many (Woods & Parker, 2013) and include failure of 
neurogenesis due to insults such as single gene defects (e.g., autosomal recessive primary 
microcephaly); chromosomal imbalance (e.g., Trisomy 21 or 7q11.23 deletion a.k.a. 
Williams syndrome); or infection (e.g., cytomegalovirus (CMV) or Toxoplasmosis).  It 
may also arise from physical damage such as hypoxia/ischemia or toxicity due to 
uncontrolled maternal PKU or other metabolic defects.  Individuals with primary 
microcephaly will usually have some degree of intellectual disability and developmental 
delay, ranging from mild to severe.  
 Secondary, acquired or progressive microcephaly occurs when the brain (and 
head) fails to grow adequately during infancy and childhood.  Head circumference may 
be small to normal at birth, but eventually becomes significantly smaller than average.  
The slowing or cessation of postnatal brain growth can be caused by any factor, intrinsic 
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or extrinsic, that interferes with proliferation and maintenance of neurons (Woods & 
Parker, 2013). 
 Macrocephaly, by contrast, refers to an OFC that is greater than two (or three; see 
above) standard deviations larger than average, suggesting a larger-than-average brain 
size.  This is not necessarily due to an increased amount of brain tissue, but may be due to 
enlargement of the ventricles and accumulation of fluid within the brain 
(ventriculomegaly or hydrocephalus), which in itself can be medically problematic.  
Macrocephaly may or may not be seen with autism spectrum disorders, (Barnard-Brak, 
Sulak, & Hatz, 2011; Grandgeorge, Lemonnier, & Jallot, 2013), which are often but not 
always associated with intellectual deficits.  Macrocephaly is a feature of many genetic 
conditions, with or without associated ID, but may also be a benign familial trait.  
   1.4.2 Seizures. 
 Seizures are involuntary, abnormal electrical events in the brain that alter the 
movement, senses and/or consciousness of the individual experiencing the seizure.  
Although the acute seizure activity is usually not continuous, individuals with seizure 
disorders demonstrate abnormal brain wave patterns by electroencephalogram (EEG) 
even when not undergoing a (recognizable) seizure.  There is an extensive list of seizure 
disorder classifications according to such criteria as physical manifestations, area of the 
brain affected, precipitating events, etc. (Berg et al., 2010; Shorvon, 2011); however all 
seizures result from an alteration of the normal electrical discharge pattern(s) of the brain.  
Seizures are very common with ID disorders, an unsurprising finding given that both 
result from disruption of the normal neuronal network.  Persons of normal intellect may 
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also have seizure disorders.  Unfortunately, seizures themselves can result in damage to 
the brain and acquired ID. 
   1.4.3 Autism spectrum disorder. 
 Autism spectrum disorder (ASD) encompasses a range of conditions that share 
the features of impaired social relationships, impaired language and communication, and 
repetitive behaviors and/or narrow range of interests (Miles, McCathren, Stichter & 
Shinawi, 2013).  Signs and symptoms are often apparent in early childhood or infancy. 
Features may develop gradually after an initially "normal" period of development, and in 
some cases (30%) may involve regression, or loss of developmental milestones.  ASD 
may be syndromic ("complex") or non-syndromic ("essential"), but involves intellectual 
disability in 50-75% of cases. Seizure disorders are a common co-morbidity, occurring in 
about 25% of affected individuals.  Up to 75% of people with ASD experience lifelong 
disability associated with the diagnosis.  Even those with average intellectual ability often 
have trouble living independently as adults (Farley et al., 2009).   
 The prevalence of ASD in the United States has increased rapidly in recent years.  
The Autism and Developmental Disabilities Monitoring (ADDM) Network within the 
Centers for Disease Control and Prevention (CDC) periodically generates reports on ASD 
prevalence, based on data about 8-year-old children at selected surveillance sites around 
the country (Centers for Disease Control and Prevention, 2014).  In 2000 and 2002, the 
ADDM Network-reported ASD prevalence was approximately 1 in 150 children.  In 
2006, the prevalence was 1 in 110, and in 2008, ASD was found in 1 in 88 children.   
 On March 28, 2014, the ADDM Network reported that, as of 2010, 1 in 68 
children in the United States had been diagnosed with ASD (ADDM Network, 2014).  
   9
This figure varied considerably according to demographic characteristics.  Consistent 
with prior data, males (1 in 42) were affected 4 to 5 times more commonly than females 
(1 in 189).  Intellectual disability was reported in 31% of children, with another 23% 
falling in the borderline range (IQ 70-85).  These rates are lower than previously 
reported, continuing the previous decade's trend of decreasing association of ID with 
ASD.  It follows that the increased prevalence of ASD is composed substantially of 
individuals with average or higher intellectual ability.  Females were more likely than 
males to have ASD with associated ID (36% of affected females vs. 30% of males). 
Caucasian (non-Hispanic) children were much more likely to be diagnosed with ASD 
than either Hispanic or African American children, and were less likely to have 
associated ID.  ASD with ID was most frequent in African-American children.  There 
was less demographic stratification among children with ASD and ID than in those with 
ASD alone.  Regional prevalence varied also, from 1 in 175 in Alabama to 1 in 45 in 
New Jersey.  The ADDM Network postulated that at least some of the demographic and 
temporal variation in prevalence is due to factors such as variable diagnostic practices 
and geographical migration driven by access to services. 
1.5 Genetic Testing for Intellectual Disability 
   1.5.1 Genetic testing methods and intellectual disability. 
 The ability to perform genetic testing for ID was established in 1959 with the 
recognition that cells from individuals with Down syndrome contained 47 chromosomes 
(rather than 46) by cytogenetic or karyotype analysis (Lejeune, Gauthier, & Turpin, 
1959).  Cytogenetic analysis is able to detect large-scale alterations in genomic dosage or 
structure, as in the above-mentioned case of Down syndrome (the presence of an extra 
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entire chromosome 21 or significant portion thereof) or Fragile X syndrome where the 
causative trinucleotide expansion changes the appearance of the X chromosome under 
certain cell culture conditions, creating a "fragile" site (Lubs, 1969).  Fragile X repeat 
expansions are now assessed using molecular methods: polymerase chain reaction (PCR) 
amplification of repeat regions and/or Southern blot protocols.  Up to 15% of individuals 
with ID may have genomic aberrations that are cytogenetically detectable (Leonard & 
Wen, 2002).  Although different preparations may affect the resolution of karyotyping, 
generally changes must encompass a minimum nucleotide size of approximately 5-10 
megabases (Mb; one million nucleotide bases) to be visible by classical cytogenetic 
techniques.  Interphase fluorescence in situ hybridization (FISH) may increase the 
resolution, with the ability to detect changes at the level of 100s of kilobases (kb; one 
thousand nucleotide bases) (Vorsanova, Yurov, & Iourov, 2010).  This resolution is still 
at the whole-gene/several gene level in many cases.  More recently, array-based 
techniques such as comparative genomic hybridization (or aCGH) have been employed to 
recognize chromosomal microdeletions and microduplications that are not visible by 
cytogenetic methods.  While aCGH may identify putative pathogenic variants in an 
additional 15% of patients with ID over those whose underlying genetic etiologies are 
identified by the classical cytogenetic techniques, microarray studies have led to the 
discovery of an enormous degree of copy number variation between individual genomes, 
much of which is of unclear significance (Bui, Vetro, Zuffardi, & Shaffer, 2011).  For 
instance, a recent study of aCGH in individuals with ID uncovered sixteen 
microduplications or microdeletions in twelve patients, only five of which were de novo 
and presumably pathogenic (Zrnova, Vranova, Slamova, Gaillyova, & Kuglik, 2011).  
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Resolution of microarray-based analysis may be as fine as several kilobases, dependent 
upon the specific microarray platform design.  Some arrays are designed to assess the 
presence or absence of specific mutations only, including single-nucleotide changes.  
These are often carrier screening panels relying on foreknowledge of, and tiling of, 
probes for anticipated mutations; they do not assay any changes not specifically tiled on 
the array.  All of these methods have clinical utility, but are incapable of detecting 
unanticipated changes at the single- or oligonucleotide level that may deleteriously alter 
gene function.   
 Thus, when hunting for causative mutations, full gene sequencing is often the 
technique most likely to yield results.  There is a current expectation in the medical 
community that, due to the rapid advancement of technology and decreasing cost, whole-
genome (or at least whole-exome) sequencing will soon become a routine, standard-of-
care medical test (Brunham & Hayden, 2012; Drmanac, 2012).  Such genome-wide 
sequencing will inevitably uncover thousands of variants, pathogenic or otherwise.  The 
subsequent data analysis, data storage, genetic counseling and follow-up resource 
requirements, as well as ethical considerations regarding reporting of incidental or 
uncertain findings, are astronomical and currently impractical for most applications.  A 
viable compromise is to perform full-gene or full-exome sequencing on a condition-
specific gene set.  This approach has the benefit of simultaneously reducing the data 
management burden and possible genetic counseling complexities while maintaining a 
relatively high mutation identification rate.  Recently published studies have applied this 
strategy of gene panel sequencing to, for instance, childhood cancer (Plon et al., 2011); 
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epilepsy (Lemke et al., 2012); hereditary hearing loss (Baek et al., 2012); and 
mitochondrial disease (Calvo et al., 2012).   
   1.5.2 X-linked intellectual disability gene panel tests. 
 Current estimates suggest that > 10% of all ID affecting males may be due to X-
linked genetic causes (Gecz, Shoubridge, & Corbett, 2009; Ropers, 2008).  Genetic loci 
contributing to ID are significantly over-represented on the X chromosome compared 
with the autosomes (Lubs et al., 2012).  In addition, X-linked genes are more likely to be 
highly expressed in brain than autosomal genes (Nguyen & Disteche, 2006).  Therefore, 
XLID genes may be a reasonable place to look when searching for a genetic cause for ID, 
even when there is no clear family history with X-linked inheritance pattern.  City of 
Hope Molecular Diagnostic Laboratory currently offers a Sanger sequencing panel of 8 
XLID genes (City of Hope Molecular Diagnostic Laboratory, 2014).  A handful of 
commercial laboratories are currently offering XLID NextGen sequencing panels: Ambry 
Genetics (81 genes, Ambry Genetics, 2014); the University of Chicago Genetic Services 
(75 genes, the University of Chicago Genetic Services, 2014); Emory Genetics 
Laboratory (92 genes, Emory Genetics Laboratory, 2014); and Greenwood Genetic 
Center (GGC) (90 genes, GGC, 2014).  
   1.5.3 Greenwood Genetic Center X-linked intellectual disability panel. 
 The Greenwood Genetic Center is a not-for-profit clinical and diagnostic genetics 
services provider based in Greenwood, SC.  Genetic testing services are available for a 
wide variety of conditions, including intellectual disability.  In 2010 GGC began offering 
a next-generation sequencing panel test of 92 genes associated with X-linked intellectual 
disability, developed in conjunction with Emory Genetics Laboratory.  Since the panel's 
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inception, GGC has revised its reporting practices to conform with updated information 
regarding the involvement of specific genes in XLID.  Current GGC literature states that 
the panel comprises 90 XLID genes; however, results from only 89 genes were being 
reported at the time of this study (M. Friez, personal communication, February 28, 2014).  
These genes are located throughout the length of the X chromosome and include genes 
associated with both well-defined syndromes and non-syndromic ID.   
 Coding exons and flanking intronic sequences of the genes within the XLID panel 
are amplified and sequenced using next-generation sequencing (NGS) methods.  The 
results are then subjected to bioinformatic analysis (M. Friez, personal communication, 
May 16, 2013).  Laboratory results are reviewed by at least two Directors, and identified 
variants are confirmed by Sanger sequencing.  If necessary, sequence analysis of variants 
of unknown significance (VUS) is carried out on samples from appropriate family 
members (parents or siblings when available) to help distinguish pathogenic and benign 
variants.  The testing process, including bioinformatics analysis, takes approximately 
three months to complete.   
 A checklist of clinical features is included as part of the test ordering 
documentation.  Ordering physicians are asked to supply a pedigree and photographs of 
the affected individual.  Cases submitted with complete clinical information, including 
photographs, are eligible for assessment by the GGC Intellectual Disability Evaluation 
and Advice System (IDEAS) team, an international panel of experts in clinical genetics.  
Of the first 100 cases submitted for XLID panel analysis, over 50% did not include 
clinical information.  Only 22 of 100 cases were provided with sufficient clinical 
information, including photographs, to be eligible for clinical review by the IDEAS team.  
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To date, the proportion of samples provided with complete clinical information remains 
at about 20% (M. Friez, personal communication, April 4, 2013). 
1.6 Selected X-linked Intellectual Disability Genes 
   1.6.1 FMR1: Fragile X syndrome and related disorders 
 Fragile X syndrome is the most common inherited cause of intellectual disability, 
with an incidence of about 1 in 3600 to 1 in 4000 males, and 1 in 4000 to 1 in 6000 
females (National Fragile X Foundation, 2014).  Males with Fragile X syndrome have 
recognizable physical characteristics, including a long, narrow face; large and prominent 
ears; high arched palate; connective tissue abnormalities such as hyperextensible joints 
and mitral valve prolapse; and macroorchidism (Gallagher & Hallahan, 2012; Saul & 
Tarleton, 2012).  Intellectual function is usually in the moderate to severe disability 
range.  Cognitively, individuals with Fragile X often fall within the autism spectrum and 
have a characteristic intellectual-psychological profile that includes executive and 
memory deficits; attention deficits; obsessive tendencies; anxiety, aggression and social 
avoidance.  Females with Fragile X syndrome have a similar, but usually less severe, 
phenotype, with only ~25% of carrier females having IQ < 70 (Gallagher & Hallahan, 
2012; Hagerman et al., 1992).  
  The gene responsible for Fragile X syndrome, FMR1, is located at Xq27.3.  The 
gene product, Fragile X Mental Retardation Protein (FMRP), is an RNA-binding protein 
involved in translational regulation of many other proteins (Wang, Bray, & Warren, 
2012).  The Fragile X locus was originally located, and named, due to the appearance of a 
"fragile" site on affected chromosomes under certain cell culture conditions (Lubs, 1969).  
This locus was later found to contain the FMR1 gene (Verkerk et al., 1991).  The 
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promoter region of the FMR1 gene contains a tract of CGG trinucleotide repeats, the 
length of which is highly variable.  With an increasing number of repeats, the allele 
becomes more unstable and vulnerable to slippage during replication, leading to 
expansion (Fu et al., 1991).  Interestingly, this instability is primarily manifested in 
oogenesis, therefore alleles may expand when passed from female carriers but are 
unlikely to expand when transmitted by a male carrier.  Fully affected individuals have an 
allele size of more than 200, and sometimes many hundreds, of repeats.  This significant 
expansion in the repeat tract triggers abnormal hypermethylation of the affected allele, 
shutting down gene expression and depriving the cell of FMRP.  Loss of FMRP and the 
resultant misexpression of multiple proteins in neurons leads to improper synapse 
formation.  This is thought to be directly responsible for the intellectual deficits seen with 
Fragile X syndrome.   
 Tracts of 55-200 CGG repeats are known as premutations.  These unstable alleles 
carry a risk of expansion with each female generation that is correlated with the number 
of repeats; the larger the allele, the greater the chance of expansion to a full mutation.  In 
unaffected individuals, the number of CGG repeats ranges up to about 54, however 
between 45-54 repeats is considered a "gray zone" that is at risk for slight expansion.  
This expansion may create a premutation allele, but not a full mutation.  The chance of 
affected children for a "gray zone" allele carrier is therefore very low, but her 
grandchildren may be at risk if her daughter inherits a premutation allele.  
 In addition to the classic Fragile X syndrome, pre- and full-mutation alleles of 
FMR1 can lead to several other disorders.  Up to 20% of female premutation carriers 
experience primary ovarian insufficiency or POI, a condition that causes early ovarian 
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failure/menopause and can lead to infertility (Hundscheid, Braat, Kiemeney, Smits, & 
Thomas, 2001; Allingham-Hawkins et al., 1999; Conway, Hettiarachchi, Murray, & 
Jacobs, 1995).  POI is not associated with full mutation alleles.  Female premutation 
carriers may also experience anxiety or major depressive disorders (Roberts et al., 2009) 
and other problems such as thyroid disease and fibromyalgia (Rodriguez-Revenga et al., 
2009).  Male or female premutation carriers are at risk for Fragile X-associated Tremor 
Ataxia syndrome (FXTAS), an adult-onset neurodegenerative condition involving both 
neuromuscular and cognitive decline (Coffey et al., 2008; Hagerman et al., 2001).  
Because of the association of autism spectrum features with Fragile X syndrome, Fragile 
X remains a first-tier genetic test for individuals with autistic features as well as those 
with ID. 
   1.6.2 ARX  
 A detailed review of ARX genotypes and phenotypes has recently been published 
(Shoubridge, Fullston, & Gecz, 2010).  XLID due to ARX mutation ranges from mild to 
severe (Stromme, Mangelsdorf, Scheffer, & Gecz, 2002) and is most often syndromic, 
although ID may be isolated in some cases.  When syndromic, ARX-related neurological 
features include seizures (including infantile spasms), autism, dysarthria (motor speech 
disorder) and dystonia (involuntary muscle contractions) (Shoubridge et al., 2010).  
When physical malformations are present, they are limited to the brain (lissencephaly, 
hydranencephaly and agenesis of the corpus callosum) and genitalia (Kato et al., 2004).  
Chronic diarrhea has also been reported in severely affected individuals (Kato et al., 
2004). Named syndromes associated with ARX mutations include West syndrome (X-
linked infantile spasms) (Kato, Das, Petras, Sawaishi, & Dobyns, 2003) and Proud 
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syndrome (X-linked intellectual disability, agenesis of the corpus callosum, and abnormal 
genitalia) also known as X-linked Lissencephaly Abnormal Genitalia syndrome or XLAG 
(Kitamura et al., 2002; Proud, Levine, & Carpenter, 1992).   
 Mutations in the ARX gene have been found in up to 7.5% of families 
demonstrating an apparent XLID (Shoubridge et al., 2010; de Brouwer et al., 2007).  
Almost every mutation class has been reported; however, by far the most common is a 
recurring, 24-base pair duplication that increases the gene's second polyalanine tract from 
12 to 20 alanine residues.  This duplication may cause syndromic or non-syndromic ID, 
tending toward the milder end of the spectrum, but demonstrates significant phenotypic 
variability both within and between families (Turner, Partington, Kerr, Mangelsdorf, & 
Gecz, 2002).  In general, however, ARX genotype-phenotype correlation is fairly 
consistent (Olivetti & Noebels, 2012).  Female carriers of ARX mutations range from 
completely asymptomatic (often associated with mutations causing milder phenotypes in 
males) to significantly affected (Bettella et al., 2013; Bonneau et al., 2002; Kato et al., 
2004; Proud et al., 1992; Scheffer et al., 2002).  
   1.6.3 DMD 
 DMD is the largest gene in the human genome, spanning 2.4 megabases of 
genomic sequence on Xp21.2.  DMD encodes the protein dystrophin, a component of a 
multiprotein complex responsible for linking the muscle cell cytoskeleton to the 
extracellular matrix, thereby stabilizing the cell against contraction-induced damage; 
hence, the dystrophinopathies are primarily muscular disorders.  Incidence of 
dystrophinopathies is estimated at 1:3500 - 1:6000 male births (National Center for 
Biotechnology Information (NCBI), 2014; Flanigan, 2012).  Affected males are normal at 
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birth, but begin to experience muscle degeneration and weakness in childhood, eventually 
losing the ability to walk or perform self-care.  Cardiac and respiratory muscles 
degenerate as well, leading to death most commonly from cardiorespiratory failure.  
Disease severity is related to residual quantity and function of dystrophin; Becker type 
(BMD) displays later onset and slower progression associated with reduced dystrophin, 
while Duchenne type (DMD) has earlier onset, more rapid progression and (near) 
complete absence of dystrophin.  Females may also express a DMD/BMD phenotype, 
due to various phenomena that expose DMD mutations, such as skewed X-inactivation; 
uniparental disomy (UPD) X; compound heterozygosity for DMD mutations; and 
monosomy X (Turner syndrome) (Darras, Miller & Urion, 2011).  Approximately 8-18% 
of carrier females eventually develop cardiomyopathy (Hoogerwaard et al., 1999).  Rare 
families display X-linked cardiomyopathy only in both males and females, associated 
with specific mutations in the DMD gene (Neri et al., 2007). 
  DMD gene mutations, including those responsible for BMD, are frequently 
deletions (60-70% of mutations) but also include point and other mutations distributed 
throughout the entire coding region (Dent et al., 2005; Flanigan et al., 2009).  In general, 
deletions that maintain the reading frame allow production of a shortened, but partially 
functional, dystrophin molecule and milder phenotype (Monaco, Bertelson, Liechti-
Gallati, Moser, & Kunkel, 1988).  Only one DMD founder mutation has been reported 
(Flanigan, Dunn, von Niederhausern, Howard, et al., 2009).  Consistent with its large 
gene size, DMD has a high forward mutation rate, and 30% of Duchenne and 10% of 
BMD mutations occur de novo.  Because of the high frequency of pathogenic deletions 
(and duplications) in DMD, first-line testing when a dystrophinopathy is suspected is 
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multiplex ligation-dependent probe amplification or MLPA.  This test gauges the 
presence or absence of specific exons according to whether (PCR-based) amplification is 
achieved.  Second-tier testing for dystrophinopathies is sequence-based analysis for point 
mutations or small insertions/deletions not detectable by MLPA.   
 The DMD gene contains 79 exons and undergoes alternative splicing to generate 
many dystrophin isoforms, some of which are brain-specific.  Although the primary 
feature of dystrophinopathies is muscle weakness and degeneration, up to one-third of 
boys with DMD mutations also display some degree of intellectual disability.  Since the 
combination of intellectual and motor delays (i.e., global delay) is not uncommon in 
young children, it may not immediately be apparent that these signs in a toddler boy 
indicate the onset of a dystrophinopathy.  A DMD mutation causing familial ID with no 
muscle weakness has recently been reported (de Brouwer et al., 2013).  This in-frame 
deletion of a single amino acid affects the brain-specific dystrophin isoform Dp71.  For 
these reasons, DMD is included in some XLID gene panels, with the understanding that 
only about 10-35% of pathogenic DMD mutations are point/small sequence changes 
(Darras et al., 2011).  However, NextGen sequencing may still identify larger deletions 
because of failure to amplify or reduced read density compared to other exons or genes.  
Due to the large size of the gene, sequence variants that are benign or of uncertain 
significance are common (Flanigan, Dunn, von Niederhausern, Soltanzadeh, et al., 2009), 
creating challenges for interpretation of sequence-based results.   
   1.6.4 ATRX 
 ATRX is the causative gene in alpha-thalassemia mental retardation X-linked 
(ATR-X) syndrome (Gibbons, Picketts, & Higgs, 1995), which consists of severe 
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intellectual disability, facial, skeletal and urogenital abnormalities and variable, mild 
alpha-thalassamia (Gibbons, Brueton, et al., 1995; McPherson, Clemens, Gibbons, & 
Higgs, 1995). Incidence of ATRX spectrum disorders is not known.  ATRX phenotypes 
occur along a continuum that includes mild, non-syndromic ID in the least-affected 
individuals (Guerrini et al., 2000; Yntema et al., 2002).  Clinical features are rarely seen 
in female carriers, nearly all of whom (>95%) demonstrate highly skewed X-inactivation 
(XI) patterns (Stevenson, 2010).  Reports of affected females demonstrating random XI 
(Wada, Sugie, Fukushima, & Saitoh, 2005) or highly skewed inactivation of the non-
mutation-bearing X (Badens et al., 2006) suggest that the skewed XI in carrier females is 
protective.  The ATRX protein is involved in chromatin remodeling processes, including 
DNA replication and gene expression, and has been shown to play a role in certain 
cancers.  Abnormal chromatin regulation in the absence of ATRX function leads to 
dysregulation of multiple genes and pathways (Clynes & Gibbons, 2013; Clynes, Higgs, 
& Gibbons, 2013).  This, then, provides a plausible selective disadvantage for cells with 
active, ATRX mutation-bearing X chromosomes and an explanation for the highly-
skewed XI in unaffected female carriers (Migeon, 2007).   
 ATRX is a relatively large gene, at 350 kilobases of genomic sequence.  
Mutations are found in the zinc finger (exons 7-9) and helicase (exons 17-20) domains in 
about 90% of cases. 
   1.6.5 CASK 
 Unlike many forms of XLID, CASK-related ID is seen more often in females than 
in males.  The CASK phenotype classically includes significant to severe ID 
accompanied by brain (including optic) malformations, marked microcephaly (onset 
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prenatally or within the first year of life) and distinctive facial features (Moog et al., 
2011; Moog, Uyanik & Kutsche, 2013).  Brain imaging consistently shows 
pontocerebellar hypoplasia with dilated fourth ventricle.  There is reduced gyration in the 
cerebral cortex of some, but not all patients.  When affected, the male phenotype is 
variable ID with or without congenital nystagmus, cerebellar hypoplasia and micro- or 
macrocephaly (Hackett et al., 2010; Piluso et al., 2009; Tarpey et al., 2009).  CASK 
mutations may also be responsible for a subset of FG syndrome, comprising 
developmental delay, agenesis of the corpus callosum, macrocephaly, hypotonia, 
digestive disturbances and characteristic personality (Piluso et al., 2009). 
 Genotype-phenotype correlation studies have indicated that CASK mutations 
causing phenotypes in females tend to be null/inactivating and male lethal.  Male viable 
mutations are generally missense and splicing mutations that are expected to be 
hypomorphic and may be asymptomatic or penetrant in carrier females (Hackett et al., 
2010; Najm et al., 2008).  Mutations causing nystagmus are clustered at the C-terminal of 
the protein (Hackett et al., 2010).  The CASK protein is a ubiquitous serine protein kinase 
that is highly expressed in fetal brain, consistent with the phenotypes of ID and brain 
malformation. 
   1.6.6 PQBP1 
 PQBP1 encodes a polyglutamine-binding protein that is thought to play a role in 
transcriptional and splicing regulation.  Mutations in PQBP1 have been identified in 
individuals/families with a variety of named syndromes, including Sutherland-Haan, 
Hamel, Renpenning, Porteous, and Golabi-Ito-Hall, as well as periventricular heterotopia; 
these can now be grouped under "Renpenning spectrum" disorders (Germanaud et al., 
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2011; Gerrard & Renpenning, 1974; Kalscheuer et al., 2003; Kleefstra et al., 2004; 
Kunde et al., 2011; Lubs et al., 2006; Stevenson et al., 2005; Sutherland, Gedeon, Haan, 
Woodroffe, & Mulley, 1988).  Incidence/prevalence figures are not known.  Common 
features within the Renpenning spectrum include variable intellectual disability, severe 
microcephaly, craniofacial dysmorphism, velar dysfunction, sparse hair, short stature, 
lean body habitus, selective muscular atrophy and genital anomalies.  However, there is 
variability in presentation within families, and between families with identical mutations 
(Kalscheuer et al., 2003).  Some families demonstrate congenital heart defects, anal 
stenosis/atresia, spastic diplegia, hypermetropia, strabismus, hearing loss and/or other 
anomalies, while in others, ID is the only phenotype.  Autism and 
neuropsychological/behavioral problems are common.  Features may be stable or 
progressive.  Female carriers are mostly of normal intelligence, with random XI 
(Kalscheuer et al., 2003) (one notable exception reported by Fichera et al., 2005), but 
may show a slightly reduced head circumference (Germanaud et al., 2011). 
 The most common mutations seen in PQBP1 are deletions and duplications of AG 
dinucleotides within an (AG)6 tract in exon 4 (Germanaud et al., 2011; Kalscheuer et al., 
2003).  These generate frameshifts, leading to premature termination of the protein. 
PQBP1 transcripts containing premature STOP codons likely undergo nonsense-mediated 
decay, resulting in reduction or absence of PQBP1 protein (Kalscheuer et al., 2003).  
Mutant PQBP1 protein has also been shown to be mislocalized throughout the cell rather 
than confined to the nucleus (Kalscheuer et al., 2003).  Other mutations, including other 
deletions and nonsense changes, also lead to premature termination.  
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   1.6.7 L1CAM 
L1CAM at Xq28 is the gene underlying L1 syndrome spectrum disorders (Legius, 
Kaepernick, Higgins, & Glover, 1994; Schrander-Stumpel & Vos, 2010).  Phenotypic 
features are variable between and within families and include X-linked hydrocephalus 
with or without stenosis of the aqueduct of Sylvius, seizures; ID, speech delay, 
hypotonia, spastic paraplegia, agenesis of the corpus callosum and adducted thumbs (Vos 
et al., 2010).  Hirschsprung disease has been reported in individuals with L1 syndrome, 
but it is not clear whether this finding is coincidental or influenced by the L1CAM 
mutation.  ID with L1CAM mutations can range from mild to severe.  Brain MRI may be 
normal or may reveal subclinical hydrocephalus or other malformations.  Approximately 
5% of female carriers display mild features of L1 syndrome but are rarely reported to be 
severely affected (Kaepernick, Legius, Higgins, & Kapur, 1994; Vos et al., 2010).  
L1CAM mutations are almost always single- or oligonucleotide variants detectable by 
sequence analysis, and occur de novo about 7% of the time (Vos & Hofstra, 2010).  
Mutations that cause premature truncation of the L1CAM protein are associated with a 
greater likelihood of death in early childhood compared to missense mutations (Vos et 
al., 2010).   
   1.6.8 KDM5C 
 KDM5C (also known as JAR1D1C and SMCX) at Xp11.22 encodes lysine (K)- 
specific demethylase 5C, a ubiquitously expressed protein involved in chromatin 
remodeling through the removal of methyl groups from lysine 4 of histone H3 (Iwase et 
al., 2007; Tahiliani et al., 2007).  KDM5C was identified as a cause of X-linked 
intellectual disability in 2005 and has since been shown to play a role in survival of 
neurons and dendritic development (Iwase et al., 2007; Jensen et al., 2005).  Loss of 
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DNA methylation has been demonstrated at multiple loci in individuals with KDM5C 
mutations (Grafodatskaya et al., 2013), and its depletion via RNA interference results in 
de-repression of multiple neuronal target genes (Grafodatskaya et al., 2013; Tahiliani et 
al., 2007).  Interestingly, downregulation of KDM5C has been proposed as a potential 
therapeutic approach in Huntington's disease, to reverse the overexpression of neuronal 
genes triggered by mutant huntingtin (Vashishtha et al., 2013). 
 Like many other XLID genes, KDM5C mutations may lead to syndromic or non-
syndromic forms of ID.  Estimates of the KDM5C mutation frequency in XLID families 
range from 0.6% to 2.8% (Goncalves et al., 2014; Jensen et al., 2005).  When syndromic, 
associated features include variable ID, speech delay, short stature, dysmorphic facial 
features, genital anomalies, altered muscle tone, ataxia, spastic paraplegia and aggressive 
behavior (Goncalves et al., 2014; Jensen et al., 2005; Ounap et al., 2012).  Females may 
be affected as well as males, at least in part because KDM5C is one of several X 
chromosome genes that escape inactivation and are more highly expressed in females 
than in males (Johnston et al., 2008; Ounap et al., 2012).   
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Chapter 2 
 
 Phenotypes and Variants in Cases Submitted for X-Linked Intellectual Disability 
(XLID) Gene Panel Testing1 
2.1 Abstract 
 Intellectual disability (ID) refers to reduced cognitive function, apparent before 
the age of 18, that negatively affects a person's learning and adaptive capacity. 
Approximately 1-3% of the population is affected with ID, males more than females, and 
most in the mild-to-moderate range. ID creates financial, logistical and psychosocial 
challenges for affected persons and their families and caregivers. It is estimated that up to 
50% of ID has a genetic cause. Molecular genetic diagnosis may help in obtaining 
services and has important implications for family members, but can be elusive. Genes 
causing ID are known to be over-represented on the X chromosome. Over 160 X-linked 
intellectual disability (XLID) syndromes and > 100 XLID genes have been identified to 
date.  Greenwood Genetic Center (GGC) offers a next-generation sequencing panel of 
approximately 90 XLID genes. The diagnostic potential offered by large gene panels is 
offset by the challenges of interpreting variants of uncertain significance (VUS).  In this 
study, molecular and clinical data from 592 cases submitted for XLID panel testing were 
evaluated for patterns of phenotype and genotype, in order to further the understanding of 
XLID.  We found a low pathogenic hit rate, a high VUS-only rate and a general absence 
                                                        
1
 Hill-Harfe, K., Ramsey, T.B. Jr., Rogers, R.C., Walker, M. and M.J. Friez.  To be 
submitted to American Journal of Medical Genetics. 
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of statistically significant phenotypic patterns.  These results highlight the need for 
appropriate patient selection, full and accurate phenotype reporting and open sharing of 
information in order to interpret and learn from the results of genetic testing. 
2.2 Introduction 
 Intellectual Disability (ID) is defined as reduced intellectual capacity that is 
apparent before the age of 18 years, and which creates significant limitations on the 
individual's ability to learn, understand, communicate and adapt (American Association 
on Intellectual and Developmental Disabilities, AAIDD, 2013).  Intellectual capacity is 
commonly reported in terms of an Intelligence Quotient, or IQ score.  Average IQ is 
defined as a score of 100.  ID is diagnosed when an individual's IQ falls > 2 standard 
deviations below the age-appropriate mean (Tirosh & Jaffe, 2011).  ID is considered to 
begin at IQ of 70-75 and below, and can be characterized as mild, moderate, severe or 
profound, with measurable decreases in the individual's functional capacity with 
increasing ID severity.  Approximately 1-3% of the population is affected with ID, most 
in the mild-to-moderate range.  Prevalence of ID is 30-40% higher in males, perhaps 
reflecting the influence of X-linked genes on brain development and function (Leonard & 
Wen, 2002; Nguyen & Disteche, 2006). 
 ID may exist as part of a recognizable, consistent constellation of intellectual, 
physical and/or functional anomalies due to a single underlying etiology, in which case it 
is considered syndromic ID.  Common examples include Down syndrome, Fragile X 
syndrome and untreated Phenylketonuria (PKU).  Non-syndromic ID may be brought to 
attention by the child's failure to develop along a typical time course or the loss of 
developmental milestones in the absence of other significant findings.   
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 By definition, individuals with ID face difficulties in conducting the tasks of daily 
living.  In addition to their intellectual challenges, they may have significant medical and 
behavioral problems that must be managed.  Financial and logistical responsibility for 
providing care and services falls primarily on families, which can place enormous 
lifelong strain on caregivers. In addition to the financial and logistical burdens borne by 
individuals with ID and their families, there are social burdens as well.  Intellectual 
impairment remains one of the disabilities that is least understood and accepted in many 
modern cultures (Scior, 2011).  The lack of awareness can lead to negative attitudes about 
people with ID, manifested in such ways as bullying, violent/hate crimes, discrimination, 
avoidance, lack of inclusion and stigmatization (Ali et al., 2012; Scior, 2011; Werner et 
al., 2012).  Stigmatization may be directed not just toward individuals with ID, but 
toward their families, friends and associates as well, known as "courtesy" or "affiliate" 
stigma (Ali et al., 2012).  Tragically, affected individuals exposed to such negative 
attitudes often internalize them and adopt self-deprecating thoughts and attitudes ("self-
stigma"), a phenomenon that has been documented in individuals with ID for many 
decades (Ali et al., 2012). 
 The availability of state-funded services and assistance for individuals with ID 
can fluctuate considerably with changing economic climate.  Having a specific molecular 
diagnosis may help families obtain needed services.  Molecular diagnosis can also help 
guide medical management, for instance, by allowing monitoring for known 
complications, and provides a means for informed family planning decisions by family 
members.  An explanation for the child's disability, however, can by itself provide benefit 
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to the family by reducing uncertainty and frustration and allowing future planning 
(Lewis, Skirton, & Jones, 2010; Rosenthal, Biesecker, & Biesecker, 2001).  
 While some reports state that only 20% of all ID has an identifiable cause (Rauch 
et al., 2006), others estimate that genetic factors may contribute in up to 85% of all cases 
(Curry et al., 1997).  Over 100 genes implicated in ID are located on the X chromosome, 
accounting in part for the greater incidence of ID in males than in females.  The advent of 
next-generation (NextGen) sequencing technologies has allowed simultaneous analysis of 
large groups of genes more quickly and at lower cost than more traditional Sanger 
(dideoxy-) sequencing.  Within the last few years, several laboratories have begun 
offering NextGen X-linked intellectual disability panels, including Greenwood Genetic 
Center (GGC).   
 We hypothesized that analysis of the clinical and molecular data from cases 
submitted for GGC XLID panel testing might yield important insights into the genetic 
etiologies and phenotypic patterns of XLID, as well as the overall success of the XLID 
panel as a diagnostic tool.   
2.3 Materials and Methods 
   2.3.1 Data collection and curation. 
 GGC maintains a MEDGIS (Medical Genetics Information System; PSA 
Computer Consultants, Winston Salem, NC) database to track and store information on 
all patients and samples submitted for analysis.  MEDGIS can be queried to retrieve 
information based on user-specified search criteria.  For this study, MEDGIS was queried 
for all samples submitted for clinical testing via the GGC XLID panel from its inception 
through June 30, 2013.  Extracted data was transferred to an Excel spreadsheet for ease of 
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manipulation.  Following generation of the Excel file, 10 samples were chosen at random 
and the information in the spreadsheet for those samples was verified against the 
MEDGIS record, in order to check for data transfer errors.  Cases were then reviewed 
individually to make corrections and clarifications and to obtain data not retrieved in the 
initial inquiry.  During this process, several samples or variants were found to be 
inappropriate for inclusion and were excluded from the final data set. These included 7 
cases with a prior diagnosis of muscular dystrophy (MD; 6 Duchenne/Becker and one 
LAMA2-related) and one with clinically suspected MD; three cases for which the panel 
was ordered but never run; one of a pair of affected full brothers who did not represent 
independent cases; and seven variants in two genes (NXF5 and ZNF674) for which GGC 
is no longer reporting data.  In 6/7 cases with NXF5 or ZNF674 variants, the removed 
variant was the only variant found, resulting in reclassification of the case from "VUS" to 
"No Variant." 
   2.3.2 Deidentification of data. 
 Following data curation, study identification numbers were assigned and personal 
identifiers were removed from the data set as follows.  Patient data in the Excel 
spreadsheet was sorted alphabetically by patient's last/family name.  In a new column, the 
RANDBETWEEN Excel function was used to generate a random number for each of the 
patients.  The entire data set was then subjected to a 2-tier sort, first by the random 
number column and second, by the patients' GGC sample identifiers (Lab ID), to remove 
sequential alphabetical or chronological ordering from the list.  The re-ordered samples 
were then assigned sequential Study Identification (Study ID) numbers.  The columns 
containing the Study ID, Lab ID and patient name were copied into a new, password-
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protected Excel workbook to generate a Study Sample Key.  Finally, the columns 
containing identifying information were removed from the working dataset to create a 
deidentified data set for analysis. 
   2.3.3 Data preparation and statistical analysis. 
 The data set was prepared for statistical analysis using Microsoft Excel 2008 
version 12.2.3 for Mac (Excel).  Each patient/case was assigned to a single row.  Data 
categories, including demographic, phenotypic, genotypic and family studies information, 
were assigned to columns.  Phenotype information was parsed into the primary categories 
of: intellectual disability/developmental disability (ID/DD); autism; seizures; 
(craniofacial) dysmorphism; microcephaly; macrocephaly; integumentary (encompassing 
skin, hair, nails and teeth); skeletal; stature and/or habitus; heart; central nervous system 
(CNS); kidney; genital; hearing; and eyes (structural and/or functional).  Additional 
columns were created to reflect combinations of phenotypes, for instance, "Any 
Urogenital" to reflect kidney, genital or both, or "Any Physical Anomaly" to include any 
physical phenotype reported.  Each case was marked "Y" in a category if the phenotype 
was reported, and "N" if the phenotype was either specifically denied or was not reported.  
In one case, the phenotype was given as "multiple congenital anomalies" with no specific 
phenotypes reported; this case was marked "Y" for "Any Physical Anomaly" and "N" in 
all other categories.  
 XLID panel variants were classified according to the molecular nature of the 
variant and its predicted pathogenicity.  Molecular classifications were: synonymous; 
missense; nonsense; frameshift (small insertions or deletions leading to a change in 
protein reading frame); deletion (larger deletions, including those in intronic regions); 
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insertion (larger insertions or duplications, regardless of whether reading frame was 
retained); and regulatory (mutations affecting one or more nucleotides in intronic or 
regulatory regions, potentially affecting splicing or translation initiation).  Variants 
reported by GGC as "pathogenic" or "likely pathogenic" at the time of XLID panel 
analysis were considered pathogenic for the purposes of this analysis.  All others were 
considered variants of uncertain significance (VUS).  
 Data analysis was performed using Excel and IBM's Statistical Package for Social 
Sciences version 22.0 (SPSS).  Frequency statistics were generated using both Excel and 
SPSS.  SPSS was used to test associations between data subsets with chi square analysis. 
2.4 Results 
   2.4.1 Phenotype analysis. 
 Descriptive statistics of the entire XLID data set and the IDEAS and non-IDEAS 
subsets are presented in Table 2.1, Table 2.2 and Table 2.3, respectively.  After curation, 
there were a total of 592 cases, comprised of 562 male (94.9%) and 30 female (5.1%).  
The most common phenotypes reported were ID/DD (80.9%); dysmorphism (35.5%); 
autism (29.4%); seizures (22.3%); microcephaly (12.8%); skeletal anomalies (12.2%); 
and macrocephaly (10.1%).  All other phenotypic categories were reported in less than 
10% of cases.  In 15 cases (2.5%), one or more physical anomalies were reported, but 
ID/DD was not.  In 7 cases (1.2%), autism was the only reported phenotype.  There was 
no phenotypic information provided for 82 cases (13.9%). 
 The IDEAS set comprised 130 cases, 125 male (96.2%) and five female (3.8%).  
Over 99% (129/130) were reported to have ID/DD.  The single male case not reported to 
have ID/DD was an infant with multiple physical anomalies.  Other common phenotypes 
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were dysmorphism (64.6%); autism (41.5%); seizures (31.5%); microcephaly (20.8%); 
skeletal anomalies (20.0%); macrocephaly (17.7%); genital anomalies (17.7%) and heart 
defects (13.1%).  All other phenotypic categories were reported in less than 10% of the 
IDEAS cases. 
 Within the non-IDEAS cases, there were 437 male (94.6%) and 25 female (5.4%) 
cases.  Phenotype frequencies in this data subset were as follows: ID/DD 75.8%; 
dysmorphism 27.3%; autism 26.0%; seizures 19.7%; microcephaly 10.6%; skeletal 
10.0% and all other categories < 10% each.   
  In order to identify phenotypic patterns, chi square analysis was employed to test 
associations between phenotypes and combinations of phenotypes within the full (Table 
2.4) and IDEAS-only (Table 2.5) data sets.  Within the full data set, the majority of 
associations examined were not statistically significant, and many failed the criteria for 
valid chi square analysis, because one or more cells had an Expected count of less than 
five.  Among those that were both valid and statistically significant, 28 of 29 were 
positive associations.  The single negative association was between autism and 
microcephaly (p = 0.025).  Among the 28 positive associations, 22 involved ID/DD, 
including a greater likelihood of ID/DD reported in males than in females (82.2% vs. 
56.7%, p = 0.001).  Five positive associations involved seizures and physical anomaly 
categories.  The final positive association was between autism and macrocephaly (p < 
0.001).   
 In addition to associations between phenotypes, we looked at whether there was 
any association between the presence of a pathogenic variant and specific phenotypes, 
and whether the number of VUS (categorized as VUS Load: 0, low (1-2 VUS) or high (3 
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or more VUS) was associated with any phenotypes.  No valid, statistically significant 
associations were found. 
 Within the IDEAS set, only two associations both met the criteria for analytic 
validity and returned a statistically significant result.  These were a negative association 
between autism and microcephaly (p = 0.002) and a negative association between autism 
and any reported anomaly of head size or shape (p = 0.035).  Autism and macrocephaly 
were not found to be significantly associated within the IDEAS data subset (p = 0.50). 
   2.4.2 Pathogenic variants. 
 Table 2.6 provides a summary of the pathogenic variants identified within our 
data set.  There were 25 male cases (hit rate 4.4%) and three female cases (hit rate 10%) 
found to have a total of 28 pathogenic variants on XLID panel analysis.  This yielded an 
overall hit rate of 4.7%.  Within the IDEAS subset, pathogenic variants were identified in 
five males (4.0%) and one female (20.0%), giving a combined hit rate of 4.6%.  The 28 
pathogenic variants were found in 18 genes, or 20.2% of the 89 XLID panel genes for 
which GGC is currently reporting results.  Multiple cases were found to have pathogenic 
variants in ARX (five cases) and ATRX (three cases).  ARHGEF9, L1CAM, OPHN1 and 
PQBP1 each had two pathogenic variants, while the remaining 12 genes yielded one 
pathogenic variant each.  In 15 of the 28 cases, the pathogenic variant was the only 
variant found.  The remaining 13 cases had between one and four VUS in addition to the 
pathogenic variant.  
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   2.4.3 Variants of uncertain significance. 
 In addition to the 13 cases with both pathogenic variants and VUS, 339 cases 
without pathogenic variants were found to have one or more VUS, giving a VUS-only 
rate of 57.3%.  Sixty-two (18.3%) had synonymous variants only, while 277 (81.7%; or 
46.7% of all cases) had one or more non-synonymous variants.  The total number of VUS 
per case ranged from one to 10, however the majority of cases had only one (185 cases; 
54.6%) or two (102 cases; 30.1%) VUS.  VUS were found in 85 of 89 reportable genes 
on the panel.  Sixty-seven genes (75.2%) yielded VUS only.  All 18 genes for which 
pathogenic variants were found also yielded one or more VUS.  As expected, the genes 
with the largest cDNA sizes, such as HUWE1 (13.1 kb), DMD (11.1 kb), FLNA (7.9 kb), 
and ATRX (7.5 kb) gave the highest number of variants. 
 Four genes- HSD17B10, NDP, PGK1 and EBE2A- showed no variants at all 
within this set of cases.  Two hundred twenty-five cases, or 38.0%, were found to have no 
variants within the reportable genes on the XLID panel.  
   2.4.5 Family studies. 
 Family studies are often helpful when interpreting the pathogenicity of genetic 
variants.  When considering X-linked variants, maternal X-inactivation status may 
provide additional clues, as unaffected female carriers of pathogenic mutations are 
sometimes found to have a protective skewing of X-inactivation.  We sought to determine 
what proportion of the pathogenic variants and non-synonymous VUS in the full data set 
were inherited from a parent.  Among the 28 individuals bearing pathogenic variants, 
parental inheritance studies were conducted for 15 (53.6%).  The pathogenic variant was 
maternally inherited in 10 cases (66.7%) and was de novo in five cases (33.3%), 
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including both female cases.  Maternal X-inactivation studies were performed for four of 
the 25 male cases with pathogenic variants (in ARHGEF9 (two cases), OPHN1 and 
CASK); all four mothers showed random XI.  The patient's own XI pattern was studied 
for one female case with a de novo variant in SLC16A2, and her XI pattern was also 
found to be random. 
 There were 277 cases with one or more non-synonymous VUS but no pathogenic 
variants.  Family studies were performed for 102 of these cases (36.8%), with a total of 
166 non-synonymous VUS.  Two cases (1.9%), were found to have a single de novo VUS 
each, amounting to a 1.2% de novo rate among non-synonymous VUS.  For one female 
case, the VUS was found to be paternally inherited.   
 Maternal XI studies were performed for 36 cases with non-synonymous VUS but 
no pathogenic variants.  In 26/36 cases, family studies had also been performed, showing 
maternal inheritance in 25/26.  One VUS was de novo, with random maternal XI.  Among 
the cases with maternally inherited variants, XI was random in 11 mothers, moderately 
skewed in eight mothers and highly skewed in six mothers.  In the set of 10 cases for 
which maternal XI studies, but not maternal inheritance studies, were performed, two 
showed random XI, three had moderately skewed XI and five showed highly skewed XI.  
All combined, maternal XI was random in 14/36 cases (38.8%), moderately skewed in 
11/36 cases (30.6%) and highly skewed in 11/36 cases (30.6%).  A list of the genes with 
non-synonymous VUS found in cases with skewed maternal XI is presented in Table 2.8. 
 2.5 Discussion 
 The study presented here had two primary goals.  The first was to look for 
phenotypic patterns within the GGC XLID cases that might be useful in constructing 
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genotype-phenotype correlations, to increase our understanding of X-linked intellectual 
disability.  The second was to assess the utility of the current GGC XLID gene panel in 
identifying the molecular etiology of intellectual disability. 
 We found that the rate of pathogenic variants was virtually identical between the 
IDEAS group and the entire data set, at approximately 4.7%.  This hit rate is substantially 
lower than those reported for next-generation sequencing panels in other conditions, such 
as familial hearing loss (62%) (Baek et al., 2012); hereditary retinal dystrophies (56%) 
(Chen et al., 2013); epileptic disorders (48%) (Lemke et al., 2012); and infantile 
mitochondrial disease (24%) (Calvo et al., 2012).  Those studies differed from the current 
study in important ways.  First, the studies investigated small numbers (8-42) of selected 
patients or families with well-defined clinical phenotypes, some including significant 
family history of the condition under investigation.  Second, the epilepsy and retinal 
dystrophy studies examined panels of 265 and 189 genes, respectively, more than twice 
as many genes as the GGC XLID panel, while the mitochondrial disease study examined 
approximately 1000 genes. 
 We cannot exclude that there may be true pathogenic variants hiding among the 
numerous VUS in our data set.  In this study, almost 50% of cases (without pathogenic 
variants) had one or more non-synonymous VUS with the potential to negatively impact 
protein function or gene regulation.  While it was beyond the scope of this study to re-
interpret VUS, it is likely that some of them are in fact pathogenic variants.  Family 
studies are often the most useful tool in assessing the potential pathogenicity of VUS, 
however we found they were performed in less than 37% of cases with VUS.  Nine XLID 
genes are consistently associated with skewed XI in carrier females (R.C. Rogers, 
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personal communication April 4, 2014).  We found 21 cases with non-synonymous VUS 
and skewed maternal XI.  Seven of these had variants in three genes (ACSL4, ATRX and 
GRIA3) associated with skewed XI in female carriers, potentially adding to the weight of 
evidence regarding their pathogenicity.  Strikingly, six of the cases had VUS in ATRX 
and highly skewed maternal XI.  The seventh case had variants in both ACSL4 and 
GRIA3 with moderately skewed maternal XI.  Finally, while we did not find any 
statistically significant association between the "load" of VUS and phenotypes within our 
data set, the possibility remains that a multifactorial ID etiology may involve the additive 
effects of several slightly deleterious variants, both X-linked and autosomal, that current 
knowledge does not allow us to recognize. 
 With any gene panel test, the selection of which genes to assess is crucial to its 
success.  Diagnostic laboratories design gene panels based on literature reporting 
causative associations between genes and phenotypes.  However, the genetic landscape 
for many conditions, including XLID, is constantly shifting.  As more data become 
available, it becomes clear that some variants and genes that were thought to be causative 
are instead benign.  Recently, Piton, Redin & Mandel (2013) published a re-assessment 
of the roles of many X-linked genes in intellectual disability, based on large-scale exome 
sequencing data.  Their study specifically questioned the roles of 10 genes in XLID, and 
called for additional data on another 15.  Two of the genes considered highly 
questionable (ZNF674 and NXF5) are already omitted from GGC's panel reporting.  One 
case in our study had a clearly deleterious (nonsense) mutation in ZNF41, also on the 
highly questionable list.  We chose to consider that change a VUS in this analysis.  Our 
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finding that only 18 of 89 genes yielded high-confidence pathogenic variants may have 
implications for future versions of the XLID panel.  
 The identification of phenotypic patterns is only possible if phenotypes are 
actually reported.  One might expect that patients for whom an intellectual disability gene 
panel test is ordered would have ID/DD as a primary phenotype.  Within the IDEAS set, 
theoretically submitted with full phenotypic information, ID/DD was reported in nearly 
100% of cases.  When looking at only the non-IDEAS cases, however, the frequency of 
reported ID/DD was reduced by almost 25%.  The rank order of phenotype frequencies, 
however, was nearly identical between the IDEAS and non-IDEAS groups.  This 
suggests that, when phenotypic information was provided, it tended to be equivalent, 
regardless of whether the referring provider requested IDEAS panel review.  Indeed, 
despite specific guidelines for providing clinical information when requesting IDEAS 
review, a recent analysis of the first 55 IDEAS cases demonstrated that, even in this 
"best-case" scenario, phenotype reporting is consistently inconsistent (Hunter et al., 
2014).   
 It is no surprise, then, that statistically significant associations between 
phenotypes were largely absent in this analysis.  The strong positive correlation seen 
between macrocephaly and autism in these patients provided reassuring evidence that, 
when reported, phenotypes were reasonably accurate.  The majority of significant 
associations, however, were between the lack of ID/DD and the lack of other reported 
phenotypes.  In other words, an individual without reported ID/DD was highly likely (p < 
0.001) to also have no other phenotypes reported, and this was true for nearly 14% of 
cases.   
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 The apparently low success rate of the GGC XLID panel begs the question of 
whether a gene panel is the best approach for this condition, since its utility relies on 
certain assumptions (in this case, X-linked etiology and the causative roles of the 
included genes) that may not be valid.  The higher hit rates seen when using larger gene 
panels for other genetically heterogeneous conditions suggest that, if choosing a panel 
approach, more genes may be better.  A greater number of genes, however, inevitably 
means a greater burden of uncertain variants and incidental findings that must be 
interpreted and communicated.  At some point the difference between analyzing a full 
exome vs. a large gene panel, for instance 1000 genes as in the mitochondrial disease 
study, becomes academic.   
 Full exome sequencing is increasingly common in clinical use, and will likely 
become routine in the near future as technology improves and costs decrease.  Indeed, the 
current turnaround time and cost of clinical exome sequencing, for the proband alone or 
proband plus parents (trio sequencing) are equivalent to those of XLID panel testing 
(GGC, 2014; Iowa Institute of Human Genetics, 2014).  Individuals with ID frequently 
have no other phenotypic findings or family history to aid in clinical diagnosis.  For these 
patients, full exome sequencing may provide the most efficient method of molecular 
diagnosis.  One way to manage the burden of exome interpretation may be to create 
virtual gene panels within the exome data.  Analysis could proceed in a tiered fashion, 
looking at the most likely gene candidates first, and only moving to additional analysis if 
the previous group fails to provide an answer.  This approach carries its own limitations.  
Sequencing coverage is less robust with a full exome vs. selected genes, making it more 
likely that a pathogenic variant may be missed.  Full exome sequencing has the potential 
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to uncover medically actionable incidental findings, which may never come to light if 
exome data is only accessed for specific genes relevant to the indication at hand.  The 
responsibilities and liabilities surrounding reporting of incidental findings are a current 
matter of intense discussion among genetics professionals.  However, selective reporting 
of results as suggested for tiered exome reporting is in fact already in practice with the 
GGC XLID panel with the omission of some genes found on the Piton et al. (2013) 
highly questionable list.   
 It cannot be overstated that successful molecular diagnosis requires astute 
matching of patient to test.  In the hearing loss study (Baek et al., 2012), for instance, 
their 8 chosen families had strong family histories showing autosomal dominant (AD) 
inheritance of a simple, well-defined phenotype; that is, a clear genetic cause, as opposed 
to a multifactorial, teratogenic, toxic or injurious etiology.  In addition, their panel 
included all of the known causative genes for hearing loss, plus some additional 
candidate genes.  Intellectual disability, by contrast, is enormously complex, 
heterogeneous in both presentation and etiology.  Over 400 ID genes have been 
identified, roughly one-quarter of which lie on the X chromosome, but less than 10% of 
ID is estimated to be X-linked.  When assessing the success of the XLID panel, a targeted 
parallel sequencing study of susceptibility genes in childhood cancer (Plon et al., 2011) 
may provide a more valid comparison.  Like (X-linked) ID/DD, the condition is 
phenotypically and genetically heterogeneous, in many cases is multifactorial, and family 
history may be uninformative.  Even with strict inclusion criteria, their hit rate (in 45 
genes) was just 13%.   
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 Unless a family history unmistakably demonstrates X-linked inheritance, the 
average case of non-syndromic ID is far more likely to have an autosomal etiology.  
Hunter et al. (2014) noted that information on family history and prior genetic 
evaluation(s) was often missing or incomplete in the early IDEAS cases, a circumstance 
that has not improved over time for the XLID panel submissions in general (M. Friez, 
personal communication, April 4, 2014).  Further confounding the picture is the 
phenotypic heterogeneity displayed by many XLID genes.  One gene may cause both 
syndromic and non-syndromic ID, which may or may not depend on the specific 
mutation.  Carrier females may or may not display a recognizable phenotype.  With non-
syndromic ID, it is often simply not possible to match a patient to a specific genetic test, 
and it is likely that many of the submitted cases have been through several tiers of testing 
already.  A large proportion of the XLID panel submissions may represent last-ditch 
diagnostic efforts rather than genuinely suspected XLID; in other words, poor XLID 
testing candidates.  This returns us to the question of whether, if taking a shot in the dark 
anyway, it might be better to aim at a larger target (i.e., the exome).   
 The limitations of this study are in fact its most relevant findings.  Plainly put, if 
progress is to be made in clarifying the genetics of intellectual disability, more 
information is needed, both from the referring physicians and the genetics community as 
a whole.  Meaningful curation of variants requires complete, accurate and accessible 
information about the patient, the patient's genotype and the gene(s) in question.  Ideally, 
the clinical and molecular evaluation of patients would proceed in a consistent, 
systematic way, and all reporting would be standardized and freely accessible.  This 
concept is already firmly within the awareness of the genetics community, as the ability 
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to acquire genome-scale information has rapidly outpaced our ability to manage the 
information.  The trend is moving toward more open sharing of variant information, but 
is not nearly universal, nor does the currently available molecular data necessarily 
include any phenotypic information (for instance, the Exome Sequencing Project of the 
National Heart, Lung and Blood Institute (NHLBI) in the National Institutes of Health 
(NIH), available at http://evs.gs.washington.edu/EVS/).  In this example, allele 
frequencies in populations chosen for a specific condition (for instance, cardiovascular 
disease) are reported, and it is left to the investigator to assume that other genetic 
conditions are not present.  The implementation of training and infrastructure to make 
comprehensive large-scale genetic data sharing possible will require a significant long-
term commitment of funding, infrastructure and collaboration.   
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Table 2.1 
Phenotype Frequencies, All Cases 
 
 Male Female Total 
Feature n % n % n % 
All cases 562 94.9 30 5.1 592 100.0 
ID/DD 462 82.2 17 56.7 479 80.9 
Dysmorphism 201 35.8 9 30.0 210 35.5 
Autism 168 29.9 6 20.0 174 29.4 
Seizures 123 21.9 9 30.0 132 22.3 
Skeletal 70 12.5 2 6.7 72 12.2 
Microcephaly 68 12.1 8 26.7 76 12.8 
Macrocephaly 60 10.7 0 0.0 60 10.1 
Integument 50 8.9 2 6.7 52 8.8 
Genital 43 7.7 0 0.0 43 7.3 
Heart 38 6.8 1 3.3 39 6.6 
Eyes 37 6.6 0 0.0 37 6.3 
Hearing  28 5.0 3 10.0 31 5.2 
Kidney 20 3.6 2 6.7 22 3.7 
Stature/Habitus 20 3.6 1 3.3 21 3.5 
CNS 20 3.6 2 6.7 22 3.7 
Autism only 7 1.2 0 0 7 1.2 
No phenotype reported 74 13.2 8 26.7 82 13.9 
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Table 2.2  
 
Phenotype Frequencies, IDEAS Cases 
 
 Male Female Total 
Feature n % n % n % 
IDEAS cases 125 96.2 5 3.8 130 100.0 
ID/DD 124 99.2 5 100.0 129 99.2 
Dysmorphism 82 65.6 2 40.0 84 64.6 
Autism 52 41.6 2 40.0 54 41.5 
Seizures 39 31.2 2 40.0 41 31.5 
Skeletal 26 20.8 0 0.0 26 20.0 
Microcephaly 26 20.8 1 20.0 27 20.8 
Macrocephaly 23 18.4 0 0.0 23 17.7 
Integument 12 9.6 0 0.0 12 9.2 
Genital 23 18.4 0 0.0 23 17.7 
Heart 17 13.6 0 0.0 17 13.1 
Eyes 8 6.4 0 0.0 8 6.2 
Hearing  6 4.8 0 0.0 6 4.6 
Kidney 6 4.8 0 0.0 6 4.6 
Stature/Habitus 4 3.2 0 0.0 4 3.1 
CNS 2 1.6 0 0.0 2 1.5 
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Table 2.3  
Phenotype Frequencies, Non-IDEAS Cases 
 
 Male Female Total 
Feature n % n % n % 
non-IDEAS cases 437 94.6 25 5.4 462 100.0 
ID/DD 338 77.3 12 48.0 350 75.8 
Dysmorphism 119 27.2 7 28.0 126 27.3 
Autism 116 26.5 4 16.0 120 26.0 
Seizures 84 19.2 7 28.0 91 19.7 
Skeletal 44 10.1 2 8.0 46 10.0 
Microcephaly 42 9.6 7 28.0 49 10.6 
Macrocephaly 37 8.5 0 0.0 37 8.0 
Integument 38 8.7 2 8.0 40 8.7 
Genital 20 4.6 0 0.0 20 4.3 
Heart 21 4.8 1 4.0 22 4.8 
Eyes 29 6.6 0 0.0 29 6.3 
Hearing  22 5.0 3 12.0 25 5.4 
Kidney 14 3.2 2 8.0 16 3.5 
Stature/Habitus 16 3.7 1 4.0 17 3.7 
CNS 18 4.1 2 8.0 20 4.3 
Autism only 7 1.6 0 0 7 1.5 
No phenotype reported 74 16.9 8 32.0 82 17.7 
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Table 2.4 
 
Chi Square Analysis of Phenotypic Associations, All Cases 
 
Feature(s) ID/DD Autism Seizures Sex VUS Load PathVar 
Sex 0.001a 0.246 0.298 - (0.200) (0.163) 
Pathogenic Variant (PathVar) 0.865 0.343 0.414 (0.163) (0.329) - 
VUS Load 0.729 0.907 0.976 (0.200) - (0.328) 
ID/DD - < 0.001 < 0.001 0.001a 0.729 0.762 
Autism < 0.001 - 0.633 0.246 0.907 0.343 
Seizures < 0.001 0.633 - 0.298 0.976 0.411 
ID/DD + Autism, no Seizures - - - 0.540 0.651 0.665 
ID/DD + Seizures, no Autism - - - (0.181) 0.682 (0.122) 
ID/DD + Autism + Seizures - - - (0.426) (0.200) (0.474) 
Any Physical Anomaly or Dysmorphic <0.001 0.351 < 0.001 0.277 0.917 0.380 
Physical Anomaly, not Dysmorphic <0.001 0.313 0.043 0.554 0.429 0.136 
Dysmorphic, no Physical Anomalies <0.001 0.748 0.233 (0.345) 0.892 (0.810) 
Physical Anomaly other than Dysmorphic <0.001 0.490 0.011 0.615 0.359 0.531 
Dysmorphic <0.001 0.810 0.058 0.520 0.312 0.706 
ID/DD + any Physical Anomaly or Dysmorphic - 0.123 < 0.001 0.055 0.288 0.447 
ID/DD + Dysmorphic - 0.617 0.038 0.094 0.327 0.821 
ID/DD + Physical Anomaly, not Dysmorphic - 0.134 0.014 0.662 0.726 0.230 
ID/DD + Physical Anomaly other than Dysmorphic - 0.141 0.002 0.095 0.260 0.568 
ID/DD + Physical Anomaly + Dysmorphic - 0.773 0.026 0.105 0.242 0.563 
Microcephaly 0.001 0.025 0.037 (0.020) 0.897 (0.164) 
Macrocephaly < 0.001 < 0.001 0.131 (0.059) 0.563 (0.069) 
Any Head < 0.001 0.146 0.006 0.690 0.829 0.863 
Integument 0.003 0.387 0.578 (0.674) 0.543 (0.712) 
Skeletal 0.005 0.748 0.356 (0.345) 0.405 (0.345) 
Stature and/or Habitus (0.996) 0.686 0.482 (0.948) (0.882) (0.292) 
Heart 0.146 0.105 0.904 (0.461) (0.786) (0.510) 
CNS (0.658) 0.239 (0.106) (0.381) (0.026) (0.326) 
Kidney (0.507) 0.484 (0.961) (0.381) (0.094) (0.326) 
Genital 0.004 0.569 0.823 (0.116) (0.350) (0.980) 
Kidney and Genital (0.745) (0.086) (0.688) (0.539) (0.220) (0.553) 
Any Urogenital 0.005 0.751 0.757 (0.554) 0.112 (0.413) 
Hearing  0.066 0.653 0.355 (0.229) (0.626) (0.203) 
Eyes 0.029 0.963 0.760 (0.147) (0.933) (0.549) 
Hearing or Eyes 0.011 0.843 0.781 (0.995) 0.798 (0.247) 
Hearing and Eyes (0.142) 0.225 (0.108) (0.485) (0.049) (0.501) 
Skeletal and Integument (0.077) (0.912) (0.545) (0.400) (0.731) (0.067) 
Skeletal and Kidney (0.879) (0.112) (0.187) (0.569) (0.373) (0.583) 
Skeletal and Genital (0.119) 0.765 (0.210) (0.306) (0.483) (0.226) 
Skeletal and any Urogenital (0.149) 0.545 0.079 (0.804) (0.713) (0.431) 
Skeletal and Heart (0.938) (0.031) (0.741) (0.539) (0.940) (0.456) 
Skeletal and Hearing (0.745) (0.431) (0.688) (0.263) (0.407) (0.553) 
Skeletal and Eyes (0.275) (0.131) (0.340) (0.604) (0.178) (0.617) 
Skeletal and Hearing or Eyes (0.539) (0.083) (0.996) (0.405) (0.502) (0.501) 
Skeletal and Microcephaly (0.250) (0.946) (0.937) (0.382) (0.267) (0.003) 
Skeletal and Macrocephaly (0.461) (0.032) (0.860) (0.461) (0.498) (0.477) 
Skeletal and any Head (0.089) 0.168 (0.865) (0.281) (0.207) (0.292) 
Integument and Kidney (0.745) (0.962) (0.688) (0.004) (0.521) (0.553) 
Integument and Genital (0.232) (0.265) (0.187) (0.569) (0.878) (0.583) 
Integument and any Urogenital (0.338) (0.346) (0.636) (0.064) (0.957) (0.436) 
Integument and Heart (0.958) (0.601) (0.229) (0.126) (0.799) (0.617) 
Integument and Microcephaly (0.394) (0.410) (0.741) (0.539) (0.009) (0.456) 
Integument and Macrocephaly (0.167) (0.004) (0.503) (0.511) (0.980) (0.526) 
Integument and any Head (0.119) (0.216) (0.488) (0.968) (0.047) (0.324) 
Heart and Kidney (0.668) (0.784) (0.853) (0.335) (0.585) (0.297) 
Heart and Genital (0.338) (0.328) (0.353) (0.419) (0.451) (0.436) 
Heart and any Urogenital (0.436) (0.590) (0.901) (0.876) (0.315) (0.820) 
Heart and Microcephaly (0.232) (0.147) (0.340) (0.604) (0.577) (0.617) 
Heart and Macrocephaly (0.275) (0.147) (0.042) (0.604) (0.799) (0.617) 
Heart and any Head (0.941) (0.040) (0.034) (0.461) (0.825) (0.477) 
Note: p values < 0.05 were considered significant. Valid positive associations are indicated in boldface.  Valid negative associations 
are underlined. Associations that did not meet the criteria for valid chi square analysis are indicated in parentheses. VUS Load was 0, 
Low (1-2 VUS) or High (≥ 3 VUS). No cases were reported with both heart and CNS anomalies. 
aAssociated with males. 
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Table 2.5 
 
Chi Square Analysis of Phenotypic Associations, IDEAS Cases 
 
Feature(s) ID/DD Autism Seizures VUS Load 
Sex ND ND ND ND 
Pathogenic Variant (0.825) (0.676) (0.923) (0.092) 
VUS Load (0.481) 0.304 (0.489) - 
ID/DD - (0.397) (0.496) (0.481) 
Autism (0.397) - 0.437 0.304 
Seizures (0.496) 0.437 - (0.489) 
ID/DD + Autism, no Seizures - - - (0.665 
ID/DD + Seizures, no Autism - - - (0.771) 
ID/DD + Autism + Seizures - - - (0.258) 
Any Physical Anomaly or Dysmorphic (0.659) 0.893 0.749 (0.481) 
Physical Anomaly, not Dysmorphic (0.633) 0.064 0.834 (0.314) 
Dysmorphic, no Physical Anomalies (0.642) 0.796 0.900 (0.944) 
Physical Anomaly other than Dysmorphic (0.480) 0.958 0.822 (0.856) 
Dysmorphic (0.458) 0.147 0.841 (0.223) 
ID/DD + any Physical Anomaly or Dysmorphic - 0.948 0.637 (0.342) 
ID/DD + Dysmorphic - 0.198 0.746 (0.169) 
ID/DD + Physical Anomaly, not Dysmorphic - 0.064 0.834 (0.314) 
ID/DD + Physical Anomaly other than Dysmorphic - 0.917 0.726 (0.739) 
ID/DD + Physical Anomaly + Dysmorphic - 0.134 0.656 (0.123) 
Microcephaly (0.050) 0.002 0.810 (0.608) 
Macrocephaly (0.642) 0.500 0.174 (0.191) 
Any Head (0.204) 0.035 0.387 0.478 
Integument (0.749) (0.014) (0.888) (0.193) 
Skeletal (0.045) 0.722 0.131 (0.282) 
Stature and/or Habitus (0.858) (0.727) (0.775) (0.554) 
Heart (0.010) 0.276 0.359 (0.961) 
CNS (0.900) (0.807) (0.571) (0.130) 
Kidney (< 0.001) (0.206) (0.319) (0.683) 
Genital (0.030) 0.234 0.535 (0.749) 
Kidney and Genital (< 0.001) (0.140) (0.185) (0.616) 
Any Urogenital (0.045) 0.213 (0.571) (0.792) 
Hearing  (0.825) (0.206) (0.923) (0.576) 
Eyes (0.797) (0.327) (0.232) (0.336) 
Hearing or Eyes (0.749) (0.222) (0.245) (0.689) 
Hearing and Eyes (0.900) (0.230) (0.571) (0.351) 
Skeletal and Integument (0.900) (0.091) (0.571) (0.351) 
Skeletal and Kidney (< 0.001) (0.230) (0.333) (0.884) 
Skeletal and Genital (< 0.001) (0.327) (0.232) (0.791) 
Skeletal and any Urogenital (0.001) (0.441) (0.127) (0.529) 
Skeletal and Heart (< 0.001) (0.055) (0.678) (0.725) 
Skeletal and Hearing (0.930) (0.397) (0.496) (0.481) 
Skeletal and Eyes (0.930 (0.234) (0.496) (0.011) 
Skeletal and Hearing or Eyes (0.900) (0.807) (0.333) (0.117) 
Skeletal and Microcephaly (0.001) (0.150) (0.127) (0.324) 
Skeletal and Macrocephaly (0.858) (0.727) (0.775) (0.543) 
Skeletal and any Head (0.760) (0.316) (0.319) (0.513) 
Integument and Kidney (0.930) (0.397) (0.139) (0.595) 
Integument and Genital (0.930) (0.234) (0.496) (0.011) 
Integument and any Urogenital (0.900) (0.807) (0.571) (0.130) 
Integument and Heart (0.930) (0.234) (0.496) (0.011) 
Integument and Microcephaly (0.900) (0.807) (0.571) (0.351) 
Integument and Macrocephaly (0.877) (0.038) (0.946) (0.211) 
Integument and any Head (0.841) (0.075) (0.678) (0.162) 
Heart and Kidney (< 0.001) (0.087) (0.420) (0.779) 
Heart and Genital (< 0.001) (0.327) (0.246) (0.597) 
Heart and any Urogenital (< 0.001) (0.223) (0.388) (0.583) 
Heart and Microcephaly (< 0.001) (0.140) (0.946) (0.616) 
Heart and Macrocephaly (0.877) (0.140) (0.010) (0.392) 
Heart and any Head (< 0.001) (0.035) (0.058) (0.693) 
Note: p values < 0.05 were considered significant. Valid negative associations are underlined. Associations that did not meet the 
criteria for valid chi square analysis are indicated in parentheses. VUS Load was 0, Low (1-2 VUS) or High (≥ 3 VUS). No cases were 
reported with both heart and CNS anomalies. 
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Table 2.6 
 
Pathogenic Variants 
 
Study ID Sex Gene Molecular Protein Class 
534 M AP1S2 c.138C>A p.C46X N 
227 M ARHGEF9 c.865C>T p.R289X N 
354 M ARHGEF9 c.691_709del19 NS D 
164 M ARX c.441_464dup24 NS I 
508 M ARX c.315_335dup21 NS I 
040 M ARX  c.441_464dup24 NS I 
024 M ARX                 c.441_464dup24 NS I 
068 M ARX                       c.441_464dup24 NS I 
080 M ATRX c.536A>G p.N179S M 
082 M ATRX c.109C>T p.R37X N 
372 M ATRX c.4654G>T p.V1552F M 
472 M CASK c.1811T>A p.L604X N 
324 M CUL4B c.857delT FS FS 
244 M IDS c.1180+2T>C NS R 
252 M KDM5C c.3125delG FS FS 
135 F KIAA2022 c.964C>T p.R322X N 
066 M L1CAM c.3531-12G>A NS R 
598 M L1CAM c.1261G>A p.V421I M 
527 M MAOA deleted NS D 
006 M OPHN1 deletion includes exon 20 NS D 
336 M OPHN1 c.1489C>T p.R497X N 
170 F PDHA1 c.947dupC FS FS 
197 M PQBP1 c.586C>T p.R196X N 
239 M PQBP1 c.691G>A p.A231T M 
355 M RPS6KA3 c.1492G>T p.G498X N 
029 F SLC16A2 c.1A>T p.M1? R 
328 M SLC9A6 c.1236+2T>A NS R 
057 M UPF3B c.674_677delGAAA NS D 
Note: M = male. F = female. NS = not specified. Class = mutation classification.  N = nonsense. D = deletion. I = insertion. M = 
missense. FS = frameshift. R = regulatory.  
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Table 2.7 
Genes with Variants of Uncertain Significance  
Gene 
Total 
Variants Total Cases M F 
Pathogenic 
Variants Total VUS Synonymous Missense Regulatory Nonsense 
Insertions/ 
Deletions 
FLNA 49 44 41 3 0 49 21 18 9 0 1 
DMD 39 36 33 3 0 39 7 25 7 0 0 
ATRX 35 35 33 2 3 32 8 20 6 1 0 
HUWE1 27 25 23 2 0 27 6 7 14 0 0 
NHS 18 17 15 2 0 18 5 9 1 0 3 
            
SHROOM4 16 16 16 0 0 16 3 11 0 0 2 
BCOR 15 14 13 1 0 15 7 8 0 0 0 
L1CAM 16 14 13 1 2 14 4 5 7 0 0 
GRIA3 14 13 12 1 0 14 1 4 9 0 0 
PCDH19 14 14 10 4 0 14 8 6 0 0 0 
            
BRWD3 13 13 12 1 0 13 8 3 2 0 0 
FANCB 13 13 12 1 0 13 2 7 4 0 0 
MED12 12 11 11 0 0 12 4 4 3 0 1 
SYN1 12 11 11 0 0 12 3 5 4 0 0 
PDHA1 11 11 9 2 1 10 3 0 6 2 0 
            
ACSL4 10 10 8 2 0 10 1 4 5 0 0 
ATP7A 10 10 10 0 0 10 1 7 2 0 0 
FGD1 10 10 8 2 0 10 3 4 3 0 0 
NSDHL 10 9 9 0 0 10 4 3 3 0 0 
CASK 10 9 9 0 1 9 0 2 7 1 0 
            
CUL4B 10 10 10 0 1 9 1 5 4 0 0 
IDS 10 9 8 1 1 9 2 5 3 0 0 
NLGN4X 9 9 9 0 0 9 3 6 0 0 0 
OFD1 9 9 9 0 0 9 2 3 4 0 0 
MAOA 9 8 8 0 1 8 2 2 3 0 2 
            
AFF2 8 8 6 2 0 8 3 4 1 0 0 
MTM1 8 8 7 1 0 8 3 2 3 0 0 
SMC1A 8 7 7 0 0 8 1 2 5 0 0 
ARX 14 14 14 0 5 7 4 3 0 0 7 
OPHN1 9 9 9 0 2 7 2 3 2 1 1 
            
AGTR2 7 7 7 0 0 7 3 4 0 0 0 
ARHGEF6 7 6 6 0 0 7 1 4 2 0 0 
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Table 2.7 Continued 
 
 
Gene 
Total 
Variants Total Cases M F 
Pathogenic 
Variants Total VUS Synonymous Missense Regulatory Nonsense 
Insertions/ 
Deletions 
LAMP2 7 7 7 0 0 7 1 2 4 0 0 
PAK3 7 7 7 0 0 7 4 2 1 0 0 
PHF8 7 7 7 0 0 7 3 1 3 0 0 
ZNF81 7 7 7 0 0 7 1 6 0 0 0 
CDKL5 6 6 6 0 0 6 1 2 2 0 1 
            
KLF8 6 6 3 3 0 6 3 2 1 0 0 
MECP2 6 6 6 0 0 6 1 5 0 0 0 
OTC 6 6 5 1 0 6 1 1 4 0 0 
KDM5C 6 6 6 0 1 5 1 4 0 0 1 
KIAA2022 6 6 3 3 1 5 5 0 0 1 0 
            
UPF3B 6 6 6 0 1 5 0 1 2 0 3 
ABCD1 5 5 5 0 0 5 1 1 3 0 0 
DLG3 5 5 5 0 0 5 4 0 1 0 0 
FTSJ1 5 4 4 0 0 5 2 1 2 0 0 
GPC3 5 5 5 0 0 5 1 2 2 0 0 
            
IL1RAPL1 5 5 5 0 0 5 1 3 1 0 0 
SLC16A2 5 5 4 1 1 4 2 2 1 0 0 
DKC1 4 4 4 0 0 4 1 0 3 0 0 
FMR1 4 4 4 0 0 4 4 0 0 0 0 
GDI1 4 4 4 0 0 4 0 0 4 0 0 
            
GK 4 3 3 0 0 4 3 0 1 0 0 
MBTPS2 4 4 4 0 0 4 1 2 0 0 1 
MID1 4 4 3 1 0 4 2 2 0 0 0 
            
RPL10 4 4 4 0 0 4 2 1 1 0 0 
SOX3 4 4 4 0 0 4 1 2 0 0 1 
SRPX2 4 4 4 0 0 4 1 3 0 0 0 
SYP 4 4 4 0 0 4 2 1 1 0 0 
RPS6KA3 5 5 5 0 1 3 0 2 2 1 0 
            
ATP6AP2 3 3 2 1 0 3 0 1 2 0 0 
HCCS 3 3 3 0 0 3 1 0 2 0 0 
MAGT1 3 3 1 2 0 3 2 0 1 0 0 
OCRL 3 3 3 0 0 3 0 2 1 0 0 
PHF6 3 3 3 0 0 3 0 0 3 0 0 
            
PORCN 3 3 2 1 0 3 2 1 0 0 0 
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Table 2.7 Continued 
 
 
Gene 
Total 
Variants Total Cases M F 
Pathogenic 
Variants Total VUS Synonymous Missense Regulatory Nonsense 
Insertions/ 
Deletions 
TSPAN7 3 3 3 0 0 3 2 1 0 0 0 
ZNF41 3 2 2 0 0 3 0 1 1 1 0 
ARHGEF9 4 4 4 0 2 2 1 1 0 1 1 
PQBP1 4 4 4 0 2 2 1 1 1 1 0 
SLC9A6 3 3 3 0 1 2 0 1 2 0 0 
            
IGBP1 2 2 2 0 0 2 0 0 2 0 0 
PLP1 2 2 2 0 0 2 1 0 1 0 0 
ZNF711 2 2 0 2 0 2 2 0 0 0 0 
AP1S2 2 2 2 0 1 1 0 0 1 1 0 
DCX 1 1 1 0 0 1 1 0 0 0 0 
            
HPRT1 1 1 1 0 0 1 0 0 1 0 0 
NDUFA1 1 1 1 0 0 1 0 1 0 0 0 
NLGN3 1 1 1 0 0 1 0 1 0 0 0 
PRPS1 1 1 1 0 0 1 1 0 0 0 0 
RAB39B 1 1 1 0 0 1 1 0 0 0 0 
            
SMS 1 1 1 0 0 1 0 1 0 0 0 
TIMM8A 1 1 1 0 0 1 0 0 1 0 0 
ZDHHC15 1 1 1 0 0 1 0 1 0 0 0 
ZDHHC9 1 1 1 0 0 1 0 0 1 0 0 
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Table 2.8 
Non-synonymous Variants Associated with Skewed Maternal X-inactivation 
Study 
ID 
Gene Molecular Protein Maternal Maternal 
XI 
104 CDKL5 c.555-19C>G NS - HS 
105 ATRXa  c.5048 A>G p.Y1683C Y HS 
125 DMD c.2630T>G p.V877G - HS 
143 ATRXa c.5038A>T p.I1680F Y HS 
196 ATRXa c.2923G>A p.D975N Y HS 
196 FANCB c.127T>A p.L43I Y HS 
196 ZNF81 c.8C>T p.A3V Y HS 
291 ATP7A c.1009G>A p.A337T Y HS 
291 HCCS c.1-2C>T NS Y HS 
357 OFD1 c.1543-19 C>G NS - HS 
545 ATRXa c.5786A>G p.K1929R - HS 
545 HUWE1 c.4824+8_4824+9insA NS - HS 
573 ATRXa c.4981C>T p.R1661C Y HS 
573 SHROOM4 c.3411_3413delGGA NS Y HS 
592 MAGT1 c.769-16T>C NS Y HS 
592 NSDHL c.268-15_268-14insT NS Y HS 
596 ATRXa c.5786A>G p.K1929R - HS 
596 HUWE1 c.4824+8_4824+9insA NS - HS 
      
062 GDI1 c.991+7 C>T NS Y MS 
062 SYN1 c.1056-14_1056-8del CTTGTC NS Y MS 
092 FANCB c.676A>G p.I226V Y MS 
156 FGD1 c.1202C>T p.A401V Y MS 
308 FANCB c.362G>A p.R121H - MS 
308 TIMM8A IVS1-6C>T NS - MS 
356 PHF8  c.1-1 G>A NS Y MS 
360 DMD c.5182C>T p.R1728C - MS 
410 AFF2 c.2569-21G>A NS Y MS 
410 IDS c.641C>T p.T214M Y MS 
434 SRPX2 c.980 A>G p.N327S Y MS 
473 ATP6AP2 c.38-5T>C NS Y MS 
473 BCOR c.2423T>A p.L808H Y MS 
473 BCOR c.2424T>C p.L808H Y MS 
473 FLNA c.3035C>T p.S1012L Y MS 
473 FLNA c.5290G>A p.A1764T Y MS 
473 OFD1 c.2387+11C>T NS Y MS 
473 PDHA1 c.832-24_832-21delAACT NS Y MS 
473 SYN1 c.528-19C>T NS Y MS 
521 ACSL4a c.1384A>G p.I462V - MS 
521 DMD c.668C>T p.P223L - MS 
521 GRIA3a c.2647G>A p.G883S - MS 
600 DMD c.5355G>C p.Q1785H Y MS 
Note: all cases with non-synonymous VUS and skewed maternal XI were male. NS = not specified. Y = maternally inherited. - = no 
family studies performed. HS = highly skewed. MS = moderately skewed.  
a
 Gene associated with skewed XI in female carriers  
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Chapter 3: Conclusions 
 
 The limitations of this study are in fact its most relevant findings.  Plainly put, if 
progress is to be made in clarifying the genetics of intellectual disability, more 
information is needed, both from the referring physicians and the genetics community as 
a whole.  Meaningful curation of variants requires complete, accurate and accessible 
information about the patient, the patient's genotype and the gene(s) in question.  Ideally, 
the clinical and molecular evaluation of patients would proceed in a consistent, 
systematic way, and all reporting would be standardized and freely accessible.  This 
concept is already firmly within the awareness of the genetics community, as the ability 
to acquire genome-scale information has rapidly outpaced our ability to manage the 
information.  The trend is moving toward more open sharing of variant information, but 
is not nearly universal, nor does the currently available molecular data necessarily 
include any phenotypic information (for instance, the Exome Sequencing Project of the 
National Heart, Lung and Blood Institute (NHLBI) in the National Institutes of Health 
(NIH), available at http://evs.gs.washington.edu/EVS/).  In this example, allele 
frequencies in populations chosen for a specific condition (for instance, cardiovascular 
disease) are reported, and it is left to the investigator to assume that other genetic 
conditions are not present.  The implementation of training and infrastructure to make 
comprehensive large-scale genetic data sharing possible will require a significant long-
term commitment of funding, infrastructure and collaboration.   
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Appendix A: X-linked Intellectual Disability Panel Variants 
Table A.1  
X-linked Intellectual Disability Panel Variants 
 
Study ID Sex Gene Molecular Protein Class  Interpretation 
070 M ABCD1 c.1634+12 C>T NS R VUS 
446 M ABCD1 c.1489-6delC NS R VUS 
450 M ABCD1 c.108G>A p.V36V S VUS 
456 M ABCD1 c.1489-6delC NS R VUS 
225 M ABCD1  c.1429G>A p.E477K  M VUS 
       
070 M ACSL4 c.308G>C p.S103T M VUS 
109 M ACSL4 c.929+3 A>G NS R VUS 
122 M ACSL4 c.1978+11 A>G NS R VUS 
152 M ACSL4 c.1821-10 G>A NS R VUS 
193 F ACSL4 c.1448A>G p.Y483C M VUS 
       
257 M ACSL4 c.82A>G p.I28V M VUS 
298 M ACSL4 c.1054-9T>A NS R VUS 
521 M ACSL4 c.1384A>G p.I462V M VUS 
529 M ACSL4 c.72C>T p.A24A S VUS 
553 F ACSL4 c.1514-7T>C NS R VUS 
       
133 M AFF2 c.3088A>C p.I1030L M VUS 
222 M AFF2 c.3268T>A p.F1090I M VUS 
250 F AFF2 c.3837 A>G het p.T1279T S VUS 
362 F AFF2 c.3701C>G p.T1234S M VUS 
365 M AFF2 c.180T>C p.Y60Y S VUS 
       
410 M AFF2 c.2569-21G>A NS R VUS 
575 M AFF2 c.496 C>T p.P166S M VUS 
490 M AFF2  c.294A>G p.P98P S VUS 
233 M AGTR2 c.402delT p.F134F S VUS 
304 M AGTR2 c.127C>T p.H43Y M VUS 
       
220 M AP1S2 c.289-10delT NS R VUS 
534 M AP1S2 c.138C>A p.C46X N P 
144 M ARHGEF6 c.2331+9G>C NS R VUS 
200 M ARHGEF6 c.2051C>T p.S684F M VUS 
200 M ARHGEF6 c.334+7C>T NS R VUS 
       
500 M ARHGEF6 c.540A>G  p.S180S S VUS 
509 M ARHGEF6 c.2093T>C p.I698T M VUS 
224 M ARHGEF6  c.1483 A>G p.K495E M VUS 
283 M ARHGEF6  c.2309G>A p.S770N M VUS 
119 M ARHGEF9 c.1094G>A p.R365H M VUS 
       
227 M ARHGEF9 c.865C>T p.R289X N P 
354 M ARHGEF9 c.691_709del19 NS D P 
570 M ARHGEF9  c.30C>T p.I10I S VUS 
018 M ARX c.1318_1320 dup GGC NS I VUS 
053 M ARX c.665_670dupGCACCG NS I VUS 
       
088 M ARX c.303A>G p.A101A S VUS 
164 M ARX c.441_464dup24 NS I P 
196 M ARX c.1671G>A p.T557T S VUS 
267 M ARX c.904G>A p.A302T M VUS 
508 M ARX c.315_335dup21 NS I P 
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Table A.1 Continued 
 
 
Study ID Sex Gene Molecular Protein Class  Interpretation 
519 M ARX c.611G>A p.R204H M VUS 
559 M ARX c.590G>A p.G197D M VUS 
562 M ARX c.336A>G p.A112A S VUS 
568 M ARX c.1671G>A p.T557T S VUS 
040 M ARX  c.441_464dup24 NS I P 
       
024 M ARX                 c.441_464dup24 NS I P 
068 M ARX                       c.441_464dup24 NS I P 
338 F ATP6AP2 c.268C>G p.P90A M VUS 
403 M ATP6AP2 c.397-13A>G NS R VUS 
473 M ATP6AP2 c.38-5T>C NS R VUS 
       
046 M ATP7A c. 3801+6T>C NS R VUS 
186 M ATP7A c.3589A>G p.N1197D M VUS 
219 M ATP7A c.4312G>A p.V1438I M VUS 
291 M ATP7A c.1009G>A p.A337T M VUS 
311 M ATP7A c.3801+6T>C NS R VUS 
       
429 M ATP7A c.1400C>G p.T467S M VUS 
456 M ATP7A c.1302A>C p.A434A S VUS 
587 M ATP7A c.3790A>G p.I1264V M VUS 
603 M ATP7A c.1009G>A p.A337T M VUS 
547 M ATP7A  c.4223 A>G p.K1408R M VUS 
       
005 M ATRX c.4120+4A>C NS R VUS 
047 M ATRX c.2127T>C p.D709D S VUS 
053 M ATRX c.2692G>C p.D898H M VUS 
080 M ATRX c.536A>G p.N179S M LP 
082 M ATRX c.109C>T p.R37X N P 
       
106 M ATRX c.1257G>A p.A419A S VUS 
116 M ATRX c.4317G>A p.K1439K S VUS 
142 M ATRX c.366 A>G p.P122P S VUS 
143 M ATRX c.5038A>T p.I1680F M VUS 
148 M ATRX c.1467C>T p.T489T S VUS 
       
178 M ATRX c.2595C>G p.H865Q M VUS 
180 M ATRX c.6110+15A>G NS R VUS 
190 M ATRX c.5395G>A p. V1799V S VUS 
196 M ATRX c.2923G>A p.D975N M VUS 
206 F ATRX c.2785C>G p.Q929E M VUS 
       
208 M ATRX c.5811 G>A p.G1937G S VUS 
217 M ATRX c.2806 G>C p.V936L M VUS 
235 M ATRX c.5579A>G p.N1860S M VUS 
238 M ATRX c.4120+4 A>C NS R VUS 
359 M ATRX c.2521A>G p.I841V M VUS 
       
362 F ATRX c.662+11T>C NS R VUS 
372 M ATRX c.4654G>T p.V1552F M P 
430 M ATRX c.5579A>G p.N1860S M VUS 
442 M ATRX c.6327-18C>T NS R VUS 
458 M ATRX c.763A>C p.A255C M VUS 
       
473 M ATRX c.5349A>G p.P1783P S VUS 
486 M ATRX c.2000C>T p.P667L M VUS 
491 M ATRX c.242+9A>G NS R VUS 
512 M ATRX c.5579A>G p.N1860S M VUS 
524 M ATRX c.3065G>A p.R1022Q M VUS 
       
545 M ATRX c.5786A>G p.K1929R M VUS 
573 M ATRX c.4981C>T p.R1661C M VUS 
591 M ATRX c.563G>C p.R188T M VUS 
596 M ATRX c.5786A>G p.K1929R M VUS 
105 M ATRX  c.5048 A>G p.Y1683C M VUS 
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022 M BCOR c.1448 C>T p.P483L M VUS 
072 M BCOR c.909C>T p.A303A S VUS 
126 M BCOR c.4899 G>A p.S1633S S VUS 
135 F BCOR c.64A>G p.M22L M VUS 
164 M BCOR c.1257A>G p.K419K S VUS 
       
176 M BCOR c.1241C>G p.A414G M VUS 
218 M BCOR c.4113G>A p.S1371S S VUS 
258 M BCOR c.277T>G p.L93V M VUS 
308 M BCOR c.1791C>T p.H597H S VUS 
       
354 M BCOR c.1084G>A p.A362T M VUS 
418 M BCOR c.3036C>T p.P1012P S VUS 
471 M BCOR c.3378C>T p.H1126H S VUS 
473 M BCOR c.2423T>A p.L808H M VUS 
473 M BCOR c.2424T>C p.L808H M VUS 
       
541 M BCOR c.4829C>T p.T1610I M VUS 
046 M BRWD3 c.3875G>A p.R1292Q M VUS 
050 M BRWD3 c.492 A>G p.S164S S VUS 
082 M BRWD3 c.1644C>T p.Y548Y S VUS 
233 M BRWD3 c.3194G>A p.G1065E M VUS 
       
280 M BRWD3 c.1386+11T>C NS R VUS 
345 M BRWD3 c.33G>A p.E11E S VUS 
407 M BRWD3 c.4210T>C p.Y1404H M VUS 
427 M BRWD3 c.3540T>C p.T1180T S VUS 
428 F BRWD3 c.5100T>C p.G1700G S VUS 
       
438 M BRWD3 c.1206 G>A p.V402V  S VUS 
542 M BRWD3 c.4008 T>G p.G1336G S VUS 
555 M BRWD3 c.1521+13T>C  NS R VUS 
604 M BRWD3 c.858T>C p.T286T S VUS 
115 M CASK c.1314+18 T>C NS R VUS 
       
173 M CASK c.1503+3 A>G NS R VUS 
201 M CASK c.1-11C>T N/A R VUS 
218 M CASK c.1234-20A>G NS R VUS 
218 M CASK c.1668+10T>C NS R VUS 
361 M CASK c.2506-11T>C NS R VUS 
       
424 M CASK c.1718C>T p.T573I M VUS 
472 M CASK c.1811T>A p.L604X N P 
513 M CASK c.1289G>A p.R430H M VUS 
529 M CASK c.1034-6C>T NS R VUS 
101 M CDKL5 c.413C>T p.P138L M VUS 
       
104 M CDKL5 c.555-19C>G NS R VUS 
272 M CDKL5 c.1431T>C p.S477S S VUS 
436 M CDKL5 c.103A>C p.T35P M VUS 
499 M CDKL5 c.1455_1460delGGCCAA p.A486_K487del D VUS 
289 M CDKL5  c.145+17 A>G NS R VUS 
       
009 M CUL4B c.831-12C>T NS R VUS 
057 M CUL4B c.65G>A p.G22D M VUS 
087 M CUL4B c.1183C>T p.R395W M VUS 
167 M CUL4B c.2298 G>T p.E766D M VUS 
248 M CUL4B c.1311-19delT NS R VUS 
       
273 M CUL4B c.831-12C>T NS R VUS 
324 M CUL4B c.857delT NS R LP 
462 M CUL4B c.1911C>T p.C637C S VUS 
474 M CUL4B c.1796 G>T p.G599V M VUS 
130 M CUL4B  c.373 C>G p.L125V M VUS 
       
    72
Table A.1 Continued 
 
Study ID Sex Gene Molecular Protein Class  Interpretation 
107 M DCX c.339C>A p.I113I S VUS 
186 M DKC1 c.771+13G>A NS R VUS 
292 M DKC1 c.1167 G>A p.K389K S VUS 
326 M DKC1 c.171+14delA NS R VUS 
407 M DKC1 c.171+14delA NS R VUS 
       
141 M DLG3 c.1405+5_1405+7 del GAG NS R VUS 
204 M DLG3 c.1782 G>A p.P594P S VUS 
253 M DLG3 c.1800T>C p.Y600Y S VUS 
345 M DLG3 c.1938C>T p.S646S S VUS 
332 M DLG3  c.2280 T>C p.Y760Y S VUS 
       
070 M DMD c.1537 A>G p.M513V M VUS 
070 M DMD c.10836 C>T  p.S3612S S VUS 
071 M DMD c.7542+13 A>G NS R VUS 
125 M DMD c.2630T>G p.V877G M VUS 
136 M DMD c.6409G>C p.E2137Q M VUS 
       
141 M DMD c.2352 T>C p.A784A S VUS 
160 M DMD c.8110 T>C p.W2704R M VUS 
160 M DMD c.10565 C>T p.A3522V M VUS 
162 M DMD c.6732G>C p.Q2244H M VUS 
178 M DMD c.4798G>C p.V1600L M VUS 
       
182 M DMD c.6614+8G>A NS R VUS 
198 M DMD c.5146G>A p.V1716M M VUS 
218 M DMD c.483C>T p.T161T S VUS 
219 M DMD c.3951G>A p.E1317E S VUS 
222 M DMD c.7472A>G p.Q2491R M VUS 
       
256 M DMD c.2380+11 G>A NS R VUS 
287 M DMD c.1993-2_1993-1insCACA NS R VUS 
301 M DMD c.7183 G>A p.A2395T M VUS 
336 M DMD c.10262+1G>A NS R VUS 
338 F DMD c.4529A>G p.K1510R M VUS 
       
360 M DMD c.5182C>T p.R1728C M VUS 
370 M DMD c.6202 C>T p.P2068S M VUS 
379 M DMD c.1095 A>C p.Q365H M VUS 
393 F DMD c.8543A>G p.H2848R M VUS 
399 M DMD c.4233+2C>T NS R VUS 
       
427 M DMD c.538C>T p.L180L S VUS 
448 M DMD c.7602C>T p.A2534A S VUS 
469 M DMD c.1337A>G p.H446R M VUS 
488 M DMD c.3674T>C p.I1225T M VUS 
492 F DMD c.10442A>G p.Q3481R M VUS 
       
496 M DMD c.6571C>T p.R2191W M VUS 
501 M DMD c.8308 G>A  p.D2770N  M VUS 
511 M DMD c.1252A>T p.T418S M VUS 
511 M DMD c.5154+14T>A NS R VUS 
521 M DMD c.668C>T p.P223L M VUS 
       
538 M DMD c.7321A>C p.T2441P M VUS 
551 M DMD c.9033 G>A p.P3011P S VUS 
600 M DMD c.5355G>C p.Q1785H M VUS 
404 M DMD  c.9352G>A p.A3118T      M VUS 
557 M DMD  c.2900T>G p.L967R M VUS 
       
018 M FANCB c.1105-3_1105-2insTATT NS R VUS 
067 M FANCB c.1769T>C p.F590S M VUS 
092 M FANCB c.676A>G p.I226V M VUS 
135 F FANCB c.493G>C p.G165R M VUS 
196 M FANCB c.127T>A p.L43I M VUS 
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217 M FANCB c.513 G>A p.Q171Q S VUS 
219 M FANCB c.1197+19_1197+21delCTT NS R VUS 
308 M FANCB c.362G>A p.R121H M VUS 
518 M FANCB c.1105-3_1105-2insTATT NS R VUS 
598 M FANCB c.507T>C p.S169S S VUS 
       
601 M FANCB c.1327-3delT NS R VUS 
603 M FANCB c.2090C>T p.P697L M VUS 
544 M FANCB  c.1177C>T p.P393S M VUS 
034 M FGD1 c.2043 C>T p.V681V S VUS 
119 M FGD1 c.110C>T p.A37V M VUS 
       
156 M FGD1 c.1202C>T p.A401V M VUS 
219 M FGD1 c.676G>A p.A226T M VUS 
225 M FGD1 c.2082G>A p.T694T  S VUS 
414 F FGD1 c.2581-6C>T NS R VUS 
456 M FGD1 c.942C>A p.P314P S VUS 
       
492 F FGD1 c.1936-11A>C NS R VUS 
540 M FGD1 c.676G>A p.A226T M VUS 
152 M FGD1  c.1101+20 NS R VUS 
005 M FLNA c.63C>T p.V21V S VUS 
025 M FLNA c.1029C>T p.S343S S VUS 
       
029 F FLNA c.5239_5250del12 NS D VUS 
044 M FLNA c.2410G>A p.V804I M VUS 
044 M FLNA c.6769+17C>G NS R VUS 
064 M FLNA c.5972C>T p.S1991L M VUS 
066 M FLNA c.6303G>A p.T2101T S VUS 
       
123 M FLNA c.2331C>T p.P777P S VUS 
131 M FLNA c.5217+13 G>T NS R VUS 
139 M FLNA c.6651 G>A p.K2214K S VUS 
156 M FLNA c.5193G>A p.V1731V S VUS 
166 M FLNA c.4866 C>T p.Y1622Y S VUS 
       
176 M FLNA c.4451A>G p.Q1484R M VUS 
184 M FLNA c.1286C>T p.T429M M VUS 
207 M FLNA c.220G>C p.G74R M VUS 
214 F FLNA c.3429C>G p.T1143T S VUS 
223 M FLNA c.1900 C>G p.R364G M VUS 
       
271 M FLNA c.3650A>G p.H1217R M VUS 
272 M FLNA c.2845G>A p.V949I M VUS 
284 M FLNA c.1693C>T p.P565S M VUS 
284 M FLNA c.4499T>C p.V1500A M VUS 
305 M FLNA c.1812 C>T p.D604D S VUS 
       
316 M FLNA c.5313+18A>G NS R VUS 
316 M FLNA c.720+8C>T NS R VUS 
321 M FLNA c.1829-13T>C NS R VUS 
321 M FLNA c.6516G>A p.Q2172Q S VUS 
345 M FLNA c.3915G>A p.T1305T S VUS 
       
354 M FLNA c.1429+8C>T NS R VUS 
371 M FLNA c.4517C>T p.T1506I M VUS 
414 F FLNA c.1875C>T p.D625D S VUS 
427 M FLNA c.7221C>T p.N2407N S VUS 
436 M FLNA c.6612C>T p.P2204P S VUS 
       
455 M FLNA c.5911A>T p.I1971F M VUS 
462 M FLNA c.861C>T p.Y287Y S VUS 
473 M FLNA c.3035C>T p.S1012L M VUS 
473 M FLNA c.5290G>A p.A1764T M VUS 
481 M FLNA c.1875C>T p.D625D S VUS 
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485 M FLNA c.4598+8G>C NS R VUS 
532 M FLNA c.6412 G>T  p.G2138C M VUS 
546 M FLNA c.622+16G>A NS R VUS 
550 M FLNA c.6408C>T p.G2136G S VUS 
560 M FLNA c.3876 C>T p.H1292H S VUS 
       
563 M FLNA c.6412G>T p.G2138C M VUS 
579 M FLNA c.1608C>T p.G536G S VUS 
585 M FLNA c.7351 G>A p.V2451I M VUS 
224 M FLNA  c.5392 A>C p.T1798P M VUS 
351 M FLNA  c.1716 C>T p.T572T S VUS 
       
353 M FLNA  c.5687-12 G>A NS R VUS 
431 M FLNA  c.6651G>A p.K2217K S VUS 
345 M FMR1 c.1857C>T p.D619D S VUS 
350 M FMR1 c.1813C>T p.L605L S VUS 
354 M FMR1 c.1695T>C p.N565N S VUS 
       
442 M FMR1 c.309C>T p.Y103Y S VUS 
003 M FTSJ1 c.984+8C>T NS R VUS 
003 M FTSJ1 c.362-20C>T NS R VUS 
043 M FTSJ1 c.219T>C p.A73A S VUS 
117 M FTSJ1 c.831G>A p.T277T S VUS 
       
552 M FTSJ1 c.349G>A p.G117R M VUS 
062 M GDI1 c.991+7 C>T NS R VUS 
104 M GDI1 c.587+15G>T NS R VUS 
331 M GDI1 c.154-20T>A NS R VUS 
381 M GDI1 c.1191+12 G>A NS R VUS 
       
372 M GK c.877-12delT NS R VUS 
459 M GK c.1479 G>A p.A493A  S VUS 
592 M GK c.1575T>C p.S525S S VUS 
592 M GK c.501C>T p.A167A S VUS 
053 M GPC3 c.1426A>T p.M476L M VUS 
       
065 M GPC3 c.1574-7_1574-4delTTGA NS R VUS 
363 M GPC3 c.1680C>T p.S560S S VUS 
494 M GPC3 c.1285G>A p.V429M M VUS 
533 M GPC3 c.1167-8T>C NS R VUS 
038 M GRIA3 c.1501-8T>A NS R VUS 
       
170 F GRIA3 c.1501-13dupT NS R VUS 
195 M GRIA3 c.1-17T>C NS R VUS 
195 M GRIA3 c.-2_-1insG NS R VUS 
221 M GRIA3 c.-16T>C NS R VUS 
222 M GRIA3 1878-3T>C NS R VUS 
       
314 M GRIA3 c.1501-13_1501-12insT NS R VUS 
317 M GRIA3 c.1852C>A p.Q618K M VUS 
426 M GRIA3 c.1501-8T>A NS R VUS 
442 M GRIA3 c.1181G>A p.R394Q M VUS 
521 M GRIA3 c.2647G>A p.G883S M VUS 
       
535 M GRIA3 c.2097C>T p.Y699Y S VUS 
552 M GRIA3 c.1878-3T>C NS R VUS 
555 M GRIA3 c.419A>G p.Q140R M VUS 
018 M HCCS c.608+13 G>A NS R VUS 
291 M HCCS c.1-2C>T NS R VUS 
       
364 M HCCS c.654 C>T p.C218C S VUS 
336 M HPRT1 c.384+19A>G NS R VUS 
001 F HUWE1 c.7338+15C>T NS R VUS 
005 M HUWE1 c.6914A>G p.D2305G M VUS 
059 M HUWE1 c.10621A>G p.T3541A M VUS 
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122 M HUWE1 c.5885-8T>C NS R VUS 
140 M HUWE1 c.5716+5G>A NS R VUS 
140 M HUWE1 c.6031-4T>A NS R VUS 
144 M HUWE1 c.694-8dupT NS R VUS 
161 M HUWE1 c.9817 C>T p.H3273Y M VUS 
       
162 M HUWE1 c.3966G>A p.L1322L S VUS 
186 M HUWE1 c.5091A>G p.G1697G S VUS 
194 M HUWE1 c.12860C>T p.S4287F M VUS 
234 M HUWE1 c.144+18C>T NS R VUS 
245 M HUWE1 c.5716+15C>T NS R VUS 
       
270 M HUWE1 c.8298A>G p.Q2766Q S VUS 
278 M HUWE1 c.6031-4T>A NS R VUS 
278 M HUWE1 c.5716+5G>A NS R VUS 
304 M HUWE1 c.5885-8T>C NS R VUS 
370 M HUWE1 c.3624 G>C p.K1208N M VUS 
       
421 M HUWE1 c.3966G>A p.L1322L S VUS 
431 M HUWE1 c.7662G>A p.T2554T S VUS 
445 M HUWE1 c.646-18 T>C NS R VUS 
492 F HUWE1 c.12364C>T p.R4122C M VUS 
523 M HUWE1 c.1673-12 A>C NS R VUS 
       
545 M HUWE1 c.4824+8_4824+9insA NS R VUS 
592 M HUWE1 c.3912A>G p.T1304T S VUS 
596 M HUWE1 c.4824+8_4824+9insA NS R VUS 
604 M HUWE1 c.3433G>A p.E1145K M VUS 
193 F IDS c.1159G>A p.A387T M VUS 
       
244 M IDS c.1180+2T>C NS R LP 
292 M IDS c.23G>T p.R8L M VUS 
410 M IDS c.641C>T p.T214M M VUS 
433 M IDS c.1222C>T p.P408S M VUS 
458 M IDS c.123C>G p.L41L S VUS 
       
458 M IDS c.126C>T p.I42I S VUS 
530 M IDS c.1222C>T p.P408S M VUS 
535 M IDS c.1181-13C>T NS R VUS 
568 M IDS c.1181-13C>T NS R VUS 
311 M IGBP1 c.872-3T>C NS R VUS 
       
329 M IGBP1 c.-18 G>C NS R VUS 
241 M IL1RAPL1 c.1927A>G p.I643V M VUS 
282 M IL1RAPL1 c.1490G>A p.R497Q M VUS 
436 M IL1RAPL1 c.1136A>G p.K379R M VUS 
483 M IL1RAPL1 c.1202-6_1202-5insT NS R VUS 
       
555 M IL1RAPL1 c.1605G>T p.T535T S VUS 
013 M JARID1C c.1607G>T p.G536V M VUS 
384 M JARID1C c.3778G>T p.A1260S M VUS 
190 M KDM5C c.1203C>T p. A401A S VUS 
252 M KDM5C c.3125delG NS FS P 
       
588 M KDM5C c.2726G>A p.R909Q M VUS 
605 M KDM5C c.3755G>A p.R1252H M VUS 
135 F KIAA2022 c.964C>T p.R322X N P 
183 F KIAA2022 c.1983 C>T p.H661H S VUS 
360 M KIAA2022 c.813A>G p.E271E S VUS 
       
362 F KIAA2022  c.637A>C p.R213R S VUS 
565 M KIAA2022 c.2088C>T p.G696G S VUS 
418 M KIAA2022  c.3756C>T p.S1252S S VUS 
135 F KLF8 c.322A>G p.I108V M VUS 
225 M KLF8 c.411T>G p.T137T S VUS 
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360 M KLF8 c.93T>C p.S31S S VUS 
396 F KLF8 c.97C>T p.R33W M VUS 
553 F KLF8 c.1-14C>T NS R VUS 
559 M KLF8 c.795G>A p.S265S S VUS 
066 M L1CAM c.3531-12G>A NS R LP 
       
085 M L1CAM c.3057T>G p.D1019E M VUS 
100 M L1CAM c.649A>C p.R217R S VUS 
152 M L1CAM c.1268-10 C>T NS R VUS 
207 M L1CAM c.2243T>C p.V748A M VUS 
304 M L1CAM c.3457+18C>T NS R VUS 
       
340 M L1CAM c.1704-18_1704-15delGACA NS R VUS 
345 M L1CAM c.695-21C>T NS R VUS 
404 M L1CAM c.870C>T  p.Y290Y S VUS 
444 M L1CAM c.1704-18_1704-15delGACA NS R VUS 
531 M L1CAM c.984 C>T p.T328T S VUS 
       
531 M L1CAM c.2432-12 G>A NS R VUS 
552 M L1CAM c.1880C>T p.T627M M VUS 
552 M L1CAM c.964C>T p.R322W M VUS 
553 F L1CAM c.2274G>A p.G758G S VUS 
598 M L1CAM c.1261G>A p.V421I M LP 
       
038 M LAMP2 c.661G>A p.G221R M VUS 
078 M LAMP2 c.929-9 T>C NS R VUS 
106 M LAMP2 c.741+11C>T NS R VUS 
462 M LAMP2 c.591G>A p.V197V S VUS 
522 M LAMP2 c.-4G>C NS R VUS 
       
598 M LAMP2 IVS1093+9C>T NS R VUS 
602 M LAMP2 c.907A>T p.M303L M VUS 
026 F MAGT1 c.798A>G p.Q266Q S VUS 
592 M MAGT1 c.769-16T>C NS R VUS 
396 F MAGT1  c.438A>T p.I146I S VUS 
       
004 M MAOA c.412-6C>G NS R VUS 
038 M MAOA c.1389C>T p.L463L S VUS 
074 M MAOA c.504G>T p.K168N M VUS 
137 M MAOA c.923T>C p.M308T M VUS 
215 M MAOA c.702C>T p.L234L S VUS 
       
222 M MAOA 306+16C>A N/A R VUS 
527 M MAOA ---- NS D P 
588 M MAOA c.1262+19G>A NS R VUS 
011 M MBTPS2 c.485 C>T p.T162M M VUS 
241 M MBTPS2 c.1237C>T p.H413Y M VUS 
       
247 M MBTPS2 c.366_383del18 NS D VUS 
424 M MBTPS2 c.846A>G p.L282L S VUS 
017 M MECP2 c.527 C>A p.P176H M VUS 
050 M MECP2 c.646 A>G p.S216G M VUS 
142 M MECP2 c.1135 C>T p.P379S M VUS 
       
303 M MECP2 c.1233C>T p.S411S S VUS 
318 M MECP2 c.206G>T p.G69V M VUS 
359 M MECP2 c.925C>T p.R309W M VUS 
054 M MED12 c.4428G>A p.L1476L S VUS 
142 M MED12 c.2981+13 G>A NS R VUS 
       
158 M MED12 c.2325C>G p.T775T S VUS 
158 M MED12 c.106C>A p.L36M M VUS 
231 M MED12 c.1248+15T>C NS R VUS 
294 M MED12 c.2784T>G p.A928A S VUS 
371 M MED12 c.4984G>A p.G1662S M VUS 
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407 M MED12 c.3355-8_3355-7 ins T NS R VUS 
483 M MED12 c.2351G>A p.R784H M VUS 
491 M MED12 c.82G>A p.D28N M VUS 
528 M MED12 c.6315_6320delACAGCA p.Q2106_Q2107del D VUS 
567 M MED12 c.4449 G>A p.S1483S S VUS 
       
220 M MID1 c.1443A>C p.T481T S VUS 
250 F MID1 c.704C>T p.T235I M VUS 
516 M MID1 c.2000C>T p.P667L M VUS 
591 M MID1 c.1242C>T p.Y414Y S VUS 
026 F MTM1 c.582C>T p.L194L S VUS 
       
053 M MTM1 c.422C>T p.A141V M VUS 
132 M MTM1 c.742G>A p.G248S M VUS 
350 M MTM1 c.528+7T>C NS R VUS 
441 M MTM1 c.1701C>T p.Y567Y S VUS 
456 M MTM1 c.546T>C p.H182H S VUS 
       
527 M MTM1 c.1260+17A>G NS R VUS 
348 M MTM1  c.64-14 T>C NS R VUS 
567 M NDUFA1 c.94 G>C  p.G32R M VUS 
014 M NHS c.204A>G p.P68P S VUS 
021 F NHS c.176G>A p.R59Q M VUS 
       
021 F NHS c.177C>A p.R59Q M VUS 
063 M NHS c.1499T>C p.V500A M VUS 
078 M NHS c.3323 C>T p.P1108L M VUS 
114 M NHS c.310_345 del 36 NS D VUS 
126 M NHS c.4416 C>A p.T1472T S VUS 
       
162 M NHS c.310_345 del 36 NS D VUS 
221 M NHS c.1533G>A p.E511E S VUS 
222 M NHS c.211C>T p.P71S M VUS 
250 F NHS c.513 C>T het p.L171L S VUS 
304 M NHS c.2056G>T p.A686S M VUS 
       
421 M NHS c.211C>T p.P71S M VUS 
529 M NHS c.566-11dupT NS R VUS 
542 M NHS c.618 G>A p.P206P S VUS 
583 M NHS c.211C>T p.P71S M VUS 
229 M NHS  c.1690 T>C p.S564P M VUS 
       
498 M NHS  c.302_337dup36 NS I VUS 
221 M NLGN3 c.238G>C p.G80R M VUS 
025 M NLGN4X c.695G>A p.R232Q M VUS 
044 M NLGN4X c.2405A>G p.Q802R M VUS 
053 M NLGN4X c.1194C>T p.S398S S VUS 
       
061 M NLGN4X c.2295C>G p.R765R S VUS 
104 M NLGN4X c.1785T>A p.P595P S VUS 
378 M NLGN4X c.2020G>A p.E674K M VUS 
543 M NLGN4X c.1249 C>T p.R417W M VUS 
222 M NLGN4X  c.1262A>G p.K421R M VUS 
       
468 M NLGN4X  c.1381 G>A p.A461T M VUS 
130 M NSDHL c.585 C>G p.T195T  S VUS 
175 M NSDHL c.267+10 C>G NS R VUS 
217 M NSDHL c.987 C>T p.V329V S VUS 
427 M NSDHL c.83A>G p.D28G M VUS 
       
427 M NSDHL c.987C>T p.V329V S VUS 
435 M NSDHL c.773C>T p.S258L     M VUS 
457 M NSDHL IVS789+16C>T NS R VUS 
466 M NSDHL c.1084A>G p.T362A M VUS 
548 M NSDHL c.351T>C p.F117F S VUS 
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592 M NSDHL c.268-15_268-14insT NS R VUS 
506 M OCRL c.897G>A p.M299I M VUS 
561 M OCRL c.2585C>T p.T862I M VUS 
588 M OCRL c.39+10G>A NS R VUS 
042 M OFD1 c.1416 A>G p.L472L  S VUS 
       
144 M OFD1 c.216C>T p.G72G S VUS 
186 M OFD1 c.2927A>C p.K976T M VUS 
238 M OFD1 c.1742 G>A p.C581Y M VUS 
357 M OFD1 c.1543-19 C>G NS R VUS 
363 M OFD1 c.2929-18C>T NS R VUS 
       
473 M OFD1 c.2387+11C>T NS R VUS 
507 M OFD1 c.2177G>A p.R726H M VUS 
086 M OFD1  c.*+2C>T NS R VUS 
006 M OPHN1 del incl. exon 20 NS D LP 
164 M OPHN1 c.1722G>T p.P574P S VUS 
       
180 M OPHN1 c.133G>A p.A45T M VUS 
222 M OPHN1 c.902C>T p.T301M M VUS 
288 M OPHN1 c.702+11A>C NS R VUS 
326 M OPHN1 c.832+16G>A NS R VUS 
336 M OPHN1 c.1489C>T p.R497X N P 
       
442 M OPHN1 c.1890C>G p.P630P S VUS 
482 M OPHN1 c.2144C>T p.A715V M VUS 
008 M OTC c.216+23G>A NS R VUS 
250 F OTC c.429 C>T het p.Y143Y S VUS 
421 M OTC c.718-14T>C NS R VUS 
       
431 M OTC c.299-7A>T NS R VUS 
493 M OTC c.83 G>A p.G28E M VUS 
469 M OTC  c.216+9C>T NS R VUS 
094 M PAK3 c.1518 G>A p.R506R  S VUS 
204 M PAK3 c.101 C>T p.P34L M VUS 
       
273 M PAK3 c.483A>G p.A161A S VUS 
280 M PAK3 c.993-20C>A NS R VUS 
345 M PAK3 c.208A>G p.I70V M VUS 
560 M PAK3 c.531 G>A p.E177E S VUS 
589 M PAK3 c.45 A>G p.P15P S VUS 
       
055 M PCDH19 c.2502 C>G p.N834K  M VUS 
061 M PCDH19 c.2328G>A p.L776L S VUS 
135 F PCDH19 c.540G>A p.T180T S VUS 
209 M PCDH19 c.1321G>C p.V441L M VUS 
262 F PCDH19 c.591C>T p.D197D S VUS 
       
301 M PCDH19 c.1877 C>T p.T626I M VUS 
361 M PCDH19 c.2646T>C p.A882A S VUS 
362 F PCDH19 c.1137C>T p.G379G S VUS 
378 M PCDH19 c.3175C>G p.R1059G M VUS 
400 M PCDH19 c.1745G>C p.G582A M VUS 
       
506 M PCDH19 c.6G>A p.E2E S VUS 
509 M PCDH19 c.540G>A p.T180T S VUS 
524 M PCDH19 c.2355C>T p.F785F S VUS 
580 F PCDH19 c.2821A>C p.N941H M VUS 
170 F PDHA1 c.947dupC NS FS P 
       
173 M PDHA1 c.831+15 C>T NS R VUS 
191 M PDHA1 c.831+15 C>T NS R VUS 
200 M PDHA1 c.*15G>C NS R VUS 
281 M PDHA1 c.604-14 G>A NS R VUS 
381 M PDHA1 c.1170 T>C p.S390S S VUS 
    79
Table A.1 Continued 
 
Study ID Sex Gene Molecular Protein Class  Interpretation 
427 M PDHA1 c.1008+7T>G NS R VUS 
473 M PDHA1 c.832-24_832-21delAACT NS R VUS 
520 M PDHA1 
 c.1009-24_1009-
17delTTTACACT NS D VUS 
537 M PDHA1 c.342C>T p.L114L S VUS 
580 F PDHA1 c.984T>C p.N328N S VUS 
       
213 M PHF6 c.729+4A>G NS R VUS 
312 M PHF6 c.241-17 T>C NS R VUS 
601 M PHF6 c.730-11T>G NS R VUS 
048 M PHF8 c.175C>T p.P59S M VUS 
102 M PHF8 c.2376G>A p.E792E S VUS 
       
140 M PHF8 c.2129+8C>G NS R VUS 
249 M PHF8 c.2547G>A p.V849V  S VUS 
278 M PHF8 c.2129+8C>G NS R VUS 
371 M PHF8 c.222A>G p.T74T S VUS 
356 M PHF8  c.1-1 G>A NS R VUS 
       
072 M PLP1 c.666C>T p.S222S S VUS 
112 M PLP1 c.763-3C>T NS R VUS 
053 M PORCN c.474C>T p.Y158Y S VUS 
206 F PORCN Heterozygous c.642C>T p.L214L S VUS 
474 M PORCN c.808 G>A p.E270K M VUS 
       
100 M PQBP1 c.*+6C>T NS R VUS 
197 M PQBP1 c.586C>T p.R196X N P 
239 M PQBP1 c.691G>A p.A231T M P 
370 M PQBP1 c.264 G>A p.S88S S VUS 
303 M PRPS1 c.942C>T p.S314S S VUS 
       
595 M RAB39B c.330C>T p.H110H S VUS 
107 M RPL10 c.633C>T p.A211A S VUS 
167 M RPL10 c.218 A>G p.N73S M VUS 
182 M RPL10 c.330-7A>G NS R VUS 
486 M RPL10 c.630G>A p.R210R S VUS 
       
355 M RPS6KA3 c.1492G>T p.G498X N P 
484 M RPS6KA3 c.631+18G>A N/A R VUS 
497 M RPS6KA3 c.1000-11 T>C NS R VUS 
552 M RPS6KA3 c.1884A>T p.E628D M VUS 
581 M RPS6KA3 c.1362T>G  p.D454E M VUS 
       
050 M SHROOM4 c.4066 G>A p.V1356I M VUS 
106 M SHROOM4 c.2165G>A p. R722H M VUS 
152 M SHROOM4 c.995 A>G p.D332G M VUS 
171 M SHROOM4 c.1320G>A p.Q440Q S VUS 
179 M SHROOM4 c.3408_3413 del GGAGGA NS D VUS 
       
182 M SHROOM4 c.731A>G p.N244S M VUS 
234 M SHROOM4 c.437G>A p.R146Q M VUS 
288 M SHROOM4 c.2646C>T p.Y882Y S VUS 
304 M SHROOM4 c.436C>T p.R146W M VUS 
347 M SHROOM4 c. 2896G>A p.E966K M VUS 
       
430 M SHROOM4 c.4066 G>A p.V1356I M VUS 
444 M SHROOM4 c.2481C>T p.D827D S VUS 
447 M SHROOM4 c.4195G>C p.E1399Q M VUS 
504 M SHROOM4 c.1913C>G p.S638C M VUS 
533 M SHROOM4 c.2629T>C p.C877R M VUS 
       
573 M SHROOM4 c.3411_3413delGGA NS D VUS 
029 F SLC16A2 c.1A>T p.M1? R LP 
458 M SLC16A2 c.345C>T p.P115P S VUS 
473 M SLC16A2 c.345C>T p.P115P S VUS 
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506 M SLC16A2 c.487G>A p.A163T M VUS 
523 M SLC16A2 c.17G>A p.G6E M VUS 
161 M SLC9A6 c.794-5 A>G NS R VUS 
227 M SLC9A6 c.1703G>A p.R568Q M VUS 
328 M SLC9A6 c.1236+2T>A NS R P 
       
076 M SMC1A c.1913C>T P.T638I M VUS 
138 M SMC1A c.1698 G>A p.E566E S VUS 
138 M SMC1A c.2600 T>C p.M867T M VUS 
256 M SMC1A c.412-10 C>T NS R VUS 
384 M SMC1A c.2421-20 C>T NS R VUS 
       
390 M SMC1A c.299-11T>C NS R VUS 
575 M SMC1A c.3702+18 NS R VUS 
557 M SMC1A  c.298+19A>G NS R VUS 
469 M SMS    c.44C>A p.A15D M VUS 
198 M SOX3 c.733_735dupGCC NS I VUS 
       
286 M SOX3 c.732A>C p.A244A S VUS 
304 M SOX3 c.946G>A p.G316S M VUS 
529 M SOX3 c.307C>A p.P103T M VUS 
103 M SRPX2 c.481C>A p.R161R S VUS 
271 M SRPX2 c.605G>A p.R202Q M VUS 
       
434 M SRPX2 c.980 A>G p.N327S M VUS 
443 M SRPX2 c.605G>A p.R202Q M VUS 
052 M SYN1 c.1369G>A p.A457T M VUS 
053 M SYN1 c.1063C>T p.L355L S VUS 
062 M SYN1 c.1056-14_1056-8 del CTTGTC NS R VUS 
       
070 M SYN1 c.377+5 G>A NS R VUS 
222 M SYN1 c.152C>G p.A51G M VUS 
222 M SYN1 c.1699A>G p.T567A M VUS 
410 M SYN1 c.1869C>T p.P623P S VUS 
458 M SYN1 c.1699A>G p.T567A M VUS 
       
473 M SYN1 c.528-19C>T NS R VUS 
501 M SYN1 c.1056-14_1056-8 del CTTGTC NS R VUS 
546 M SYN1 c.292_293delinsTT p.Q98L M VUS 
552 M SYN1 c.1063C>T p.L355L S VUS 
138 M SYP c.687 C>T p.A229A S VUS 
       
273 M SYP c.705G>C p.A235A S VUS 
331 M SYP c.782G>A p.G261E M VUS 
400 M SYP c.615+12G>A N/A R VUS 
308 M TIMM8A IVS1-6C>T NS R VUS 
330 M TSPAN7 c.78 C>T p.F26F S VUS 
       
381 M TSPAN7 c.78 C>T p.F26F S VUS 
533 M TSPAN7 c.515C>A p.P172H M VUS 
044 M UPF3B c.-13 G>C NS R VUS 
047 M UPF3B c.263+19dup12 NS I VUS 
057 M UPF3B c.674_677delGAAA NS D LP 
       
208 M UPF3B c.-13 G>C NS R VUS 
271 M UPF3B c.263+19dup12 NS I VUS 
526 M UPF3B c.388A>G p.I130V M VUS 
164 M ZDHHC15 c.178C>T p.L60F M VUS 
447 M ZDHHC9 c.881+3G>A NS R VUS 
       
246 M ZNF41 c.2012C>T p. A671V M VUS 
246 M ZNF41 c.2023C>T p.R675X N VUS 
510 M ZNF41 c.296-19T>C NS R VUS 
001 F ZNF711 c.1968A>G p.T656T S VUS 
021 F ZNF711 c.363C>A p.T121T S VUS 
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056 M ZNF81 c.828T>G p.C276W M VUS 
171 M ZNF81 c.18C>T p.D6D S VUS 
172 M ZNF81 c.554C>T p.S185L M VUS 
196 M ZNF81 c.8C>T p.A3V M VUS 
219 M ZNF81 c.1495A>G p.I499V M VUS 
       
499 M ZNF81 c.290G>C p.G97A M VUS 
572 M ZNF81 c.554C>T p.S185L M VUS 
 
 
 
